Modified ligand gated ion channels and methods of use

By modifying the amino acids of the LGIC subunit, chimeric LGICs with pharmacologically selectiveness were developed, and the fine regulation of cell function was achieved using exogenous ligands, which solved the problem of difficult control of endogenous ligand sensitivity in the prior art. , reduces side effects and improves the effect of treating channel diseases.

CN118903472APending Publication Date: 2024-11-08HOWARD HUGHES MEDICAL INST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410821217.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-09-11
Filing Date
2018-11-09
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art is difficult to effectively control the activity of endogenous ligands on ligand-gated ion channels (LGICs), resulting in greater side effects when treating channel diseases and it is difficult to achieve fine regulation of cell excitability and ion transport.

Method used

By modifying the LGIC subunits in amino acids, especially LBD and IPD, the sensitivity to exogenous and endogenous ligands is enhanced or reduced, thereby developing pharmacologically selective chimeric LGICs using exogenous ligands Somatically selectively activate or inhibit modified LGIC to achieve fine regulation of cellular function.

Benefits of technology

It improves the sensitivity to exogenous ligands, reduces the sensitivity to endogenous ligands, enhances the selective control of cellular function, reduces side effects, and realizes effective treatment of channel diseases and cellular excitability regulation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903472A_ABST
    Figure CN118903472A_ABST
Patent Text Reader

Abstract

This document relates to materials and methods for modulating ligand gated ion channel (LGIC) activity. For example, a modified LGIC comprising at least one LGIC subunit is provided, the LGIC subunit having a modified ligand binding domain (LBD) and / or a modified ion pore domain (IPD). Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across a mammalian cell membrane, methods of modulating cellular excitability in a mammalian, and methods of treating a mammalian with channeling disease.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of an invention patent application with an application date of November 9, 2018, a priority date of November 10, 2017, an application number of 201880085703.5, and an invention name of “Modified ligand-gated ion channels and methods of use”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims the benefit of U.S. Patent Application Serial No. 62 / 584,428, filed on November 10, 2017, and claims the benefit of U.S. Patent Application Serial No. 62 / 729,716, filed on September 11, 2018. The disclosure of the prior application is considered part of (and incorporated by reference into) the disclosure of the present application. Background of the Invention 1. Technical Field

[0005] This document relates to materials and methods for regulating the activity of ligand-gated ion channels (LGICs). For example, this document provides a modified LGIC comprising at least one LGIC subunit having a modified ligand binding domain (LBD) and / or a modified ion pore domain (IPD). An exogenous LGIC ligand is also provided that can bind to and activate the modified LGIC. In some cases, the modified LGIC and the exogenous ligand can be used to treat mammals suffering from channelopathy (e.g., neural channelopathy or muscle channelopathy). In some cases, the modified LGIC and the exogenous LGIC ligand can be used to regulate (e.g., activate or inhibit) ion transport across mammalian cell membranes. In some cases, the modified LGIC and the exogenous LGIC ligand can be used to regulate (e.g., increase or decrease) the excitability of cells in mammals.

[0006] 2. Background Information

[0007] Ion channels mediate ion flux in cells, which greatly influences their biological functions. A prominent example of this is neurons, where ion channels control electrical signaling within and / or between neurons to influence physiology, sensation, behavior, mood, and cognition.

[0008] Different LGICs have different ligand binding properties and specific ion conductance properties (Hille 2001 Ion Channels of Excitable Membranes. pp. 814. Sunderland, MA: Sinauer Associates; Kandel et al 2000 Principles of Neural Science. USA: McGraw-Hill Co. 1414 pp). For example, nicotinic acetylcholine receptors (nAChRs) bind to the endogenous ligand acetylcholine (ACh), which activates the conductance of cations and generally depolarizes the cell, thereby increasing cell excitability. In contrast, glycine receptors (GlyRs) bind to the endogenous ligand glycine, which activates chloride ion conductance and generally reduces the excitability of the cell by hyperpolarization and / or electrical shunt through the cell membrane resistance. SUMMARY OF THE INVENTION

[0010] The levels of endogenous LGIC ligands (eg, agonists) such as ACh are not easily controlled.

[0011] This document provides materials and methods for regulating LGIC activity (e.g., increasing the sensitivity of LGIC to exogenous ligands and / or reducing the sensitivity to endogenous ligands such as ACh). For example, this document provides a modified LGIC comprising at least one modified LGIC subunit having an LBD and an IPD and having at least one modified amino acid (e.g., an amino acid substitution). An exogenous LGIC ligand is also provided that can bind to and regulate (e.g., activate) the modified LGIC. In some cases, the modified LGIC and the exogenous ligand can be used to treat mammals suffering from channel diseases (e.g., neural channel diseases or muscle channel diseases). In some cases, the modified LGIC and the exogenous LGIC ligand can be used to regulate (e.g., activate or inhibit) ion transport across mammalian cell membranes. In some cases, the modified LGIC and the exogenous LGIC ligand can be used to regulate (e.g., increase or decrease) the excitability of cells in mammals.

[0012] Having the ability to control LGIC activity provides a unique and unrealized opportunity to control ion transport in cells. For example, modified LGICs with increased sensitivity to one or more exogenous LGIC ligands can be used to provide temporal and spatial control of ion transport and / or cell excitability based on the delivery of exogenous LGIC ligands. For example, modified LGICs with reduced sensitivity to endogenous LGIC ligands prevent the undesired activation of modified LGICs and allow the modified LGICs to be selectively controlled by exogenous ligands. In addition, exogenous LGIC ligands with increased efficacy to modified LGICs improve the targeting selectivity of modified LGICs relative to endogenous ion channels. Therefore, the modified LCIG and exogenous LGIC ligands provided herein can be used to achieve therapeutic effects while reducing the side effects of small molecules on unintended targets.

[0013] As described herein, one or more mutations in the modified LGIC can enhance the potency of exogenous LGIC ligands. Mutations of the α7LBD of the α7-GlyR at residue L131 (e.g., substitution of Leu with Gly or Ala) increase the potency of varenicline (16-fold) and tropisetron (3.6-fold) relative to α7-GlyR, while reducing the potency of ACh (-6.4-fold). Mutations of the α7LBD of the α7-GlyR at residues G175 (e.g., G175K) or P216 (e.g., P216I) enhance the potency of Ach, nicotine, tropisetron, varenicline, and other quinoline and tropane agonists. Combining a mutation at residue G175K with a mutation that reduces the potency of the endogenous agonist ACh (e.g., Y115F) yields an α7-GlyR Y115F G175K with increased potency (5.5-fold) for tropisetron and reduced potency (-8-fold) for Ach. In addition, combining mutations at residues 77 (e.g., substitution of Trp with Phe or Tyr) and / or 79 (e.g., substitution of Gln with Gly, Ala, or Ser) and / or 131 (e.g., substitution of Leu with Gly or Ala) and / or 141 (e.g., substitution of Leu with Phe or Pro) in these chimeric channels in the α7 LBD with potency-enhancing mutations at residues G175 (e.g., G175K) or P216 (e.g., P216I) increases the potency of the unique ligand and / or reduces Ach potency. For example, a chimeric α7-GlyRLGIC containing an α7nAChR LBD (α7LBD) having a mutation at residue 79 (e.g., substitution of Gln with Gly), a mutation at residue 115 (e.g., substitution of Tyr with Phe), and a mutation at residue 175 (e.g., substitution of Gly with Lys) has greater than 100-fold increased sensitivity to the exogenous tropane LGIC ligand Compound 723 (tropane) and decreased Ach sensitivity (-15-fold) relative to the unmodified chimeric α7-GlyR LGIC. Furthermore, the modified LGIC, comprising at least one chimeric LGIC subunit containing an α7 nAChR LBD (α7 LBD) having a mutation at residue 79 (e.g., substitution of Ala, Gly or Ser for Gln) and a GlyR IPD having a mutation at residue 298 (e.g., substitution of Gly for Ala). Additional mutations at residues 27 (e.g., substitution of Asp for Arg) and 41 (e.g., substitution of Arg for Glu) of the α7 LBD reduced binding of the modified chimeric LGIC to unmodified ion channels.Additional mutations at residues 115 (e.g., substitution of Tyr with Phe), 139 (e.g., substitution of Gln with Gly or Leu), 210 (e.g., substitution of Tyr with Phe), 217 (e.g., substitution of Tyr with Phe), and / or 219 (e.g., substitution of Asp with Ala) of the α7 LBD reduce the sensitivity of the chimeric LGIC to the endogenous ligand ACh. These chimeric LGICs allow highly selective control of cellular function in mammalian cells while minimizing cross-responsiveness with endogenous signaling systems in mammals.

[0014] In general, one aspect of this document features a modified LGIC having at least one modified LGIC subunit comprising an LBD and an IPD having amino acid modifications, wherein an exogenous LGIC ligand activates the modified LGIC. The modified LGIC can be a chimeric LGIC having an LBD from a first LGIC and an IPD from a second LGIC. The LBD can be an α7 nicotinic acetylcholine receptor (α7-nAChR) LBD. The modified LGIC of claim 3, wherein at least one modified amino acid in the α7-nAChR LBD comprises an amino acid substitution at an amino acid residue selected from the group consisting of residues 77, 79, 131, 139, 141, 175, and 216 of the α7-nAChR LBD. The amino acid substitution can be at residue 79 of the α7 LBD, and the amino acid substitution can be Q79A, Q79G, or Q79S. For example, the amino acid substitution at residue 79 of the α7 LBD can be Q79G. The IPD may be a serotonin 3 receptor (5HT3) IPD, a glycine receptor (GlyR) IPD, a γ-aminobutyric acid (GABA) receptor IPD, or an α7-nAChR IPD. The IPD may be a GlyR IPD, and the GlyR IPD may include an amino acid substitution at residue 298 of a chimeric LGIC (e.g., an A298G substitution). The IPD may be a GABA IPD, and the GABA IPD may include an amino acid substitution at residue 298 of a modified LGIC (e.g., a W298A substitution). The modified LGIC may be a chimeric LGIC comprising an α7LBD having a Q79G amino acid substitution and a GlyR IPD having an A298G amino acid substitution. The exogenous LGIC ligand can be a synthetic exogenous LGIC ligand selected from the group consisting of quinuclidine, tropane, 9-azabicyclo[3.3.1]nonane, 6,7,8,9-tetrahydro-6,10-methano-6H-pyrazino(2,3-h)benzazepine and 1,4-diazabicyclo[3.2.2]nonane. When the synthetic exogenous LGIC ligand is tropane, the tropane can be tropisetron, pseudotropisetron, nortropisetron, compound 723, compound 725, compound 737 or compound 745. When the synthesized exogenous LGIC ligand is quinuclidine, quinuclidine can be PNU-282987, PHA-543613, compound 0456, compound 0434, compound 0436, compound 0354, compound 0353, compound 0295, compound 0296, compound 0536, compound 0676, or compound 702. When the synthesized exogenous LGIC ligand is 6,7,8,9-tetrahydro-6,10-methano-6H-pyrazino(2,3-h)benzazepine, the ligand can be compound 765 or compound 770.When the synthetic exogenous LGIC ligand is 1,4-diazabicyclo[3.2.2]nonane, the ligand can be compound 773 or compound 774. In some cases, the LBD can be an α7LBD, and the α7LBD can also include at least one modified amino acid that confers selective binding to another α7LBD having at least one modified amino acid relative to binding to an unmodified LGIC. The unmodified LGIC can be an endogenous LGIC (e.g., an endogenous α7-nAChR). At least one modified amino acid in the α7LBD that confers reduced binding to the unmodified LGIC can include an amino acid substitution at residue 27 (e.g., an R27D substitution) and / or residue 41 (e.g., an E41R substitution). In some cases, the IPD can be a 5HT3IPD, and the 5HT3 IPD can include at least one modified amino acid that confers increased ionic conductance to the modified LGIC. The at least one modified amino acid in the 5HT3 IPD that confers increased ionic conductance to the modified LGIC may include an amino acid substitution at amino acid residues at residues 425 (e.g., R425Q substitution), 429 (e.g., R429D substitution), and / or 433 (e.g., R433A substitution).

[0015] In another aspect, the document herein features a modified LGIC having at least one modified LGIC subunit comprising an LBD and an IPD having at least one modified amino acid, wherein at least one modified amino acid in the LBD reduces binding to an endogenous LGIC ligand. The modified LGIC may be a chimeric LGIC having an LBD from a first LGIC and an IPD from a second LGIC. The endogenous LGIC ligand may be ACh. The modified LGIC may have an EC50 of greater than 20 μM for Ach. The at least one modified amino acid may include an amino acid substitution at residues 115, 139, 210, 217, and / or 219. When the at least one modified amino acid includes an amino acid substitution at residue 115, the amino acid substitution may be a Y115F substitution. When the at least one modified amino acid includes an amino acid substitution at residue 139, the amino acid substitution may be a Q139G or Q139L substitution. When at least one modified amino acid comprises an amino acid substitution at residue 210, the amino acid substitution may be a Y210F substitution. When at least one modified amino acid comprises an amino acid substitution at residue 217, the amino acid substitution may be a Y217F substitution. When at least one modified amino acid comprises an amino acid substitution at residue 219, the amino acid substitution may be a D219A substitution. In some cases, the modified LGIC may comprise a modified α7-nAChR LBD having an L131G amino acid substitution, a Q139L amino acid substitution, and a Y217F amino acid substitution. The modified LGIC (e.g., a modified LGIC comprising a modified α7-nAChR LBD having an L131G amino acid substitution, a Q139L amino acid substitution, and a Y217F amino acid substitution) may also comprise an endoplasmic reticulum export sequence. The endoplasmic reticulum export sequence may comprise the amino acid sequence FCYENEV (SEQ ID NO: 16). For example, a modified LGIC comprising a modified α7-nAChR LBD having an L131G amino acid substitution, a Q139L amino acid substitution, and a Y217F amino acid substitution, and further comprising an endoplasmic reticulum export sequence may comprise the amino acid sequence set forth in SEQ ID NO: 13. A modified LGIC (e.g., a modified LGIC comprising a modified α7-nAChR LBD having an L131G amino acid substitution, a Q139L amino acid substitution, and a Y217F amino acid substitution) may also comprise a signal sequence (e.g., a CHRNB4 signal sequence). The CHRNB4 signal sequence may comprise the amino acid sequence MRRAPSLVLFFLVALCGRGNC (SEQ ID NO: 17).For example, a modified LGIC comprising a modified α7-nAChR LBD having an L131G amino acid substitution, a Q139L amino acid substitution, and a Y217F amino acid substitution and further comprising a CHRNB4 signal sequence can comprise the amino acid sequence set forth in SEQ ID NO: 14. The modified LGIC (e.g., a modified LGIC comprising a modified α7-nAChR LBD having an L131G amino acid substitution, a Q139L amino acid substitution, and a Y217F amino acid substitution) can also comprise a somatic cell targeting sequence (e.g., a KCNB1 somatic cell targeting sequence). The KCNB1 somatic cell targeting sequence can comprise the amino acid sequence QSQPILNTKEMAPQSKPPEELEMSSMPSPVAPLPARTEGVIDMRSMSSIDSFISCATDFPEATRF (SEQ ID NO: 18). For example, a modified LGIC comprising a modified α7-nAChR LBD having an L131G amino acid substitution, a Q139L amino acid substitution, and a Y217F amino acid substitution and further comprising a KCNB1 somatic targeting sequence may comprise the amino acid sequence set forth in SEQ ID NO:15.

[0016] In another aspect, this document features a ligand with increased potency on a modified ligand-gated ion channel (LGIC), wherein the ligand comprises Formula I:

[0017]

[0018] Wherein X1, X2 and X3 are each independently CH, CH2, O, NH or NMe; wherein each n can be independently 0 or 1; wherein Y=O or S; wherein A=aromatic substituent; wherein R=H or pyridylmethylene. The aromatic substituent can be 1H-indole, 4-(trifluoromethyl)benzene, 2,5-dimethoxybenzene, 4-chloroaniline, aniline, 5-(trifluoromethyl)pyridin-2-yl, 6-(trifluoromethyl)nicotine, or 4-chlorobenzene.

[0019] In some cases, the LGIC ligand can be quinuclidine and can have the structure shown in Formula II:

[0020]

[0021] wherein X3=O, NH or CH2; wherein Y=O or S; wherein A=aromatic substituent; wherein R=H or pyridylmethylene. The aromatic substituent can be 1H-indole, 4-(trifluoromethyl)benzene, 4-chlorobenzene, 2,5-dimethoxybenzene, 4-(trifluoromethyl)benzene, 4-chloroaniline, aniline, 5-(trifluoromethyl)pyridin-2-yl, 6-(trifluoromethyl)nicotine, 3-chloro-4-fluorobenzene or 1H-indole. Quinucleoside can be PNU-282987, PHA-543613, Compound 0456, Compound 0434, Compound 0436, Compound 0354, Compound 0353, Compound 0295, Compound 0296, Compound 0536, Compound 0676 or Compound 702.

[0022] In some cases, the LGIC ligand can be tropane, and can have the structure shown in Formula III:

[0023]

[0024] wherein X2=NH or NMe; wherein X3=O, NH or CH2; wherein Y=O or S; wherein A=aromatic substituent. The aromatic substituent can be 1H-indole, 7-methoxy-1H-indole, 7-methyl-1H-indole, 5-chloro-1H-indole or 1H-indazole. The tropane can be tropisetron, pseudotropisetron, nortropisetron, compound 723, compound 725, compound 737 or compound 745.

[0025] In some cases, the LGIC ligand can be 9-azabicyclo[3.3.1]nonane and can have the structure shown in Formula IV:

[0026]

[0027] Wherein X1 can be CH, X2 can be NH or NMe, X3 can be O, NH or CH; Y can be O or S, and A can be an aromatic substituent. The aromatic substituent can be 4-chloro-benzene. 9-Azabicyclo[3.3.1]nonane can be compound 0536.

[0028] In another aspect, the present document features a ligand having increased potency for a modified LGIC, wherein the ligand can be 6,7,8,9-tetrahydro-6,10-methano-6H-pyrazino(2,3-h)benzazepine and can have a structure as shown in Formula V:

[0029]

[0030] wherein R1 can be H, phenyl, 2-toluoyl; 3-pyridyl; 4-pyridyl; trifluoromethyl; methoxy; N,N-dimethylamino; N,N-diethylamino; imidazole, pyrrole, pyrazole, triazole, or isoxazol-3-amine; and wherein R2 can be H, methyl or phenyl. 6,7,8,9-tetrahydro-6,10-methano-6H-pyrazino(2,3-h)benzazepine can be varenicline, compound 0765, compound 0770, compound 0780, compound 0782, compound 0785, compound 0788, compound 0782, compound 0789, compound 0791, compound 0793, compound 0794, compound 0795, compound 0798, compound 0799, compound 0800, compound 0801, compound 0802, compound 0803, compound 0804, compound 0805, compound 0807, compound 0808, compound 0812, compound 0813, compound 815, compound 816, and compound 817.

[0031] In another aspect, the present document features ligands with increased potency for modified LGICs, wherein the ligand can be 2-(pyridin-3-yl)-1,5,6,7,8,9-hexahydro-5,9-methanoimidazo[4',5':4,5]benzo[1,2-d]azepine (eg, compound 0786):

[0032]

[0033] In another aspect, the present document features a ligand having increased potency for modified LGIC, wherein the ligand can be 7,8,9,10-tetrahydro-1H-6,10-methanoazepine[4,5-g]quinoxalin-2(6H)-one and can have a structure as shown in Formula VI:

[0034]

[0035] wherein R1 may be H or CH3, wherein R2 may be H, CH3 or an aromatic substituent, and wherein R3 may be O or S. 7,8,9,10-tetrahydro-1H-6,10-methanoazepine[4,5-g]quinoxaline-2(6H)-one may be Compound 0783, Compound 0784, Compound 0790 or Compound 0792.

[0036] In another aspect, the present document features a ligand having increased potency for modified LGIC, wherein the ligand can be 1,4-diazabicyclo[3.2.2]nonane, and can have the structure shown in Formula VII:

[0037]

[0038] Wherein R can be H, F or NO2. 1,4-diazabicyclo[3.2.2]nonane can be 3-(1,4-diazabicyclo[3.2.2]non-4-yl)dibenzo[b,d]thiophene 5,5-dioxide, Compound 0773, or Compound 0774.

[0039] In another aspect, this document features a method of treating a channelopathy in a mammal. The method comprises or consists essentially of administering a modified LGIC to a mammalian cell, wherein an exogenous LGIC ligand selectively binds to the modified LGIC. The modified LGIC has at least one modified LGIC subunit comprising an LBD and an IPD comprising at least one modified amino acid; and administering the exogenous ligand to the mammal.The channelopathy can be Bartter syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), congenital hyperinsulinism, cystic fibrosis, Dravet syndrome, episodic ataxia, erythromelalgia, generalized epilepsy (e.g., with febrile seizures), familial hemiplegic migraine, fibromyalgia, hyperkalemic periodic paralysis, hypokalemic periodic paralysis, Lambert-Eaton myasthenic syndrome, long QT syndrome (e.g., Romano-Ward syndrome), syndrome), short QT syndrome, malignant hyperthermia, mucolipidosis type IV, myasthenia gravis, myotonia congenital, neuromyelitis optica, neuromyotonia, nonsyndromic deafness, paramyotonia congenital, retinitis pigmentosa, timothy syndrome, tinnitus, seizures, trigeminal neuralgia, and multiple sclerosis.

[0040] In another aspect, this document features a method of modulating ion transport across a mammalian cell membrane. The method comprises or consists essentially of administering a modified LGIC to a cell, wherein an exogenous LGIC ligand selectively binds to the modified LGIC. The modified LGIC has at least one modified LGIC subunit, the modified LGIC subunit comprising an LBD and an IPD comprising at least one modified amino acid; and administering an exogenous ligand to the mammal. Modulation may include activating or inhibiting ion transport. The cell may be a neuron, a glial cell, a muscle cell, a stem cell, an endocrine cell, or an immune cell. Administration of the modified LGIC to the cell may be in vivo or ex vivo. Administration of the modified LGIC to the cell may include administering a nucleic acid encoding the modified LGIC.

[0041] In another aspect, this document features a method of regulating cell excitability in a mammal. The method comprises or consists essentially of administering a modified LGIC to a mammalian cell, wherein an exogenous LGIC ligand selectively binds to the modified LGIC. The modified LGIC has at least one modified LGIC subunit, the modified LGIC subunit comprising an LBD and an IPD comprising at least one modified amino acid; and administering an exogenous ligand to the mammal. Regulation may include increasing the excitability of the cell or decreasing the excitability of the cell. The cell may be an excitable cell. The cell may be a neuron, a glial cell, a muscle cell, a stem cell, an endocrine cell, or an immune cell. Administration of the modified LGIC to the cell may be in vivo or ex vivo. Administration of the modified LGIC to the cell may include administration of a nucleic acid encoding the modified LGIC.

[0042] In another aspect, the document features a method of regulating cell activity in a mammal. The method comprises or consists essentially of administering a modified LGIC to a cell, wherein an exogenous LGIC ligand selectively binds to the modified LGIC. The modified LGIC has at least one modified LGIC subunit, the modified LGIC subunit comprising an LBD and an IPD comprising at least one modified amino acid; and administering an exogenous ligand to the mammal. Regulation may include increasing cell activity or decreasing cell activity. The activity may be ion transport, passive transport, excitation, inhibition, or exocytosis. The cell may be a neuron, a glial cell, a muscle cell, a stem cell, an endocrine cell, or an immune cell. Administering the modified LGIC to a cell may be in vivo or ex vivo. Administering the modified LGIC to a cell may include administering a nucleic acid encoding the modified LGIC (e.g., via a viral vector, such as an adeno-associated virus, herpes simplex virus, or a lentivirus).

[0043] In another aspect, this document features a method for identifying a ligand that selectively binds to a modified LGIC. The method comprises or consists essentially of providing one or more candidate ligands to a modified LGIC described herein, and detecting binding between the candidate ligand and the modified LGIC, thereby identifying a ligand that selectively binds to the modified LGIC. The modified LGIC can be a homomeric modified LGIC.

[0044] In another aspect, the document features a method for detecting a modified LGIC. The method comprises or consists essentially of providing one or more modified LGIC subunits described herein, providing an agent that selectively binds to the modified LGIC, and detecting binding between the modified LGIC and the agent that selectively binds to the modified LGIC, thereby detecting the modified LGIC. The agent that selectively binds to the modified LGIC comprises an antibody, a protein (e.g., a bungarus toxin), or a small molecule (e.g., a positron emission tomography (PET) ligand). The agent that selectively binds to the modified LGIC may comprise a detectable marker (e.g., a fluorescent marker, a radioactive marker, or a positron emitting marker).

[0045] In another aspect, the document features a synthetic nucleic acid construct comprising a nucleic acid sequence having at least 75% sequence identity to the sequence shown in SEQ ID NO:27. The nucleic acid sequence having at least 75% sequence identity to the sequence shown in SEQ ID NO:27 can include a nucleic acid sequence that can encode an LBD having an amino acid modification. The modified LBD can be an α7-nAChR LBD having amino acid substitution residues 77, 79, 115, 131, 139, 141, 175, 210, 216, 217 and / or 219 of the α7-nAChR LBD. The nucleic acid sequence having at least 75% sequence identity to the sequence shown in SEQ ID NO:27 can include a nucleic acid sequence that can encode an IPD. The IPD can be a 5HT3 IPD, a GlyR IPD, a GABA receptor IPD, or an α7-nAChR IPD. The IPD can be a 5HT3 IPD.

[0046] In another aspect, this document features a synthetic nucleic acid construct that includes a nucleic acid sequence that has at least 75% sequence identity to the sequence shown in SEQ ID NO:28.

[0047] A nucleic acid sequence having at least 75% sequence identity to the sequence shown in SEQ ID NO:28 may include a nucleic acid sequence that can encode an LBD having an amino acid modification. The modified LBD may be an α7-nAChR LBD having amino acid substitution residues 77, 79, 115, 131, 139, 141, 175, 210, 216, 217 and / or 219 of the α7-nAChR LBD. A nucleic acid sequence having at least 75% sequence identity to the sequence shown in SEQ ID NO:28 may include a nucleic acid sequence that can encode an IPD. The IPD may be a 5HT3 IPD, a GlyR IPD, a GABA receptor IPD, or an α7-nAChR IPD. The IPD may be a GlyR IPD having an amino acid modification. The modified GlyR IPD may have an amino acid substitution at amino acid residue 298 of the GlyR IPD.

[0048] In another aspect, the present document features a synthetic nucleic acid construct comprising a nucleic acid sequence having at least 75% sequence identity to the sequence shown in SEQ ID NO: 29. The nucleic acid sequence having at least 75% sequence identity to the sequence shown in SEQ ID NO: 29 may include a nucleic acid sequence that can encode an LBD having an amino acid modification. The modified LBD may be an α7-nAChRLBD having amino acid substitution residues 77, 79, 115, 131, 139, 141, 175, 210, 216, 217 and / or 219 of the α7-nAChR LBD. The nucleic acid sequence having at least 75% sequence identity to the sequence shown in SEQ ID NO: 29 may include a nucleic acid sequence that can encode an IPD. The IPD may be a 5HT3 IPD, a GlyR IPD, a GABA receptor IPD, or an α7-nAChR IPD. The IPD may be a GABA IPD having an amino acid modification. The modified GABA IPD may have an amino acid substitution at amino acid residue 298 of the GABA IPD.

[0049] In another aspect, this document features a synthetic nucleic acid construct having the sequence set forth in SEQ ID NO:33.

[0050] In another aspect, this document features a synthetic nucleic acid construct having the sequence set forth in SEQ ID NO:34.

[0051] The present application further relates to the following embodiments:

[0052] 1. A modified ligand-gated ion channel (LGIC), comprising at least one modified LGIC subunit, wherein the modified LGIC subunit comprises:

[0053] comprising a ligand binding domain (LBD) with amino acid modifications, and

[0054] Ion pore domain (IPD).

[0055] 2. The modified LGIC of embodiment 1, wherein the modified LGIC is a chimeric LGIC comprising an LBD from a first LGIC and an IPD from a second LGIC.

[0056] 3. The modified LGIC of embodiment 1, wherein the LBD is an α7 nicotinic acetylcholine receptor (α7-nAChR) LBD.

[0057] 4. The modified LGIC of embodiment 3, wherein the amino acid modification comprises an amino acid substitution at one or more amino acid residues selected from the group consisting of residues 77, 79, 115, 131, 139, 141, 175, 210, 216, 217 and 219 of the α7-nAChR LBD.

[0058] 5. The modified LGIC of embodiment 4, wherein the amino acid substitution is at residue 77 of the α7-nAChR LBD, and wherein the amino acid substitution is selected from the group consisting of W77F and W77Y.

[0059] 6. The modified LGIC of embodiment 4, wherein the amino acid substitution is at residue 79 of the α7-nAChR LBD, and wherein the amino acid substitution is selected from the group consisting of Q79A, Q79G and Q79S.

[0060] 7. The modified LGIC of embodiment 4, wherein the amino acid substitution is at residue 115 of the α7-nAChR LBD, and wherein the amino acid substitution is a Y115F substitution.

[0061] 8. The modified LGIC of embodiment 4, wherein the amino acid substitution is at residue 131 of the α7-nAChR LBD, and wherein the amino acid substitution is selected from the group consisting of L131A, L131G, L131M and L131N.

[0062] 9. The modified LGIC of embodiment 4, wherein the amino acid substitution is at residue 139 of the α7-nAChR LBD, and wherein the amino acid substitution is selected from the group consisting of Q139G and Q139L.

[0063] 10. The modified LGIC of embodiment 4, wherein the amino acid substitution is at residue 175 of the α7-nAChR LBD, and wherein the amino acid substitution is selected from the group consisting of G175A, G175F, G175H, G175K, G175M, G175R, G175S and G175V.

[0064] 11. The modified LGIC of embodiment 4, wherein the amino acid substitution is at residue 210 of the α7-nAChR LBD, and wherein the amino acid substitution is a Y210F substitution.

[0065] 12. The modified LGIC of embodiment 4, wherein the amino acid substitution is at residue 216 of the α7-nAChR LBD, and wherein the amino acid substitution is a P216I substitution.

[0066] 13. The modified LGIC of embodiment 4, wherein the amino acid substitution is at residue 217 of the α7-nAChR LBD, and wherein the amino acid substitution is a Y217F substitution.

[0067] 14. The modified LGIC of embodiment 4, wherein the amino acid substitution is at residue 219 of the α7-nAChR LBD, and wherein the amino acid substitution is a D219A substitution.

[0068] 15. The modified LGIC of embodiment 4, wherein the α7-nAChR LBD comprises an L131G amino acid substitution, a Q139L amino acid substitution, and a Y217F amino acid substitution.

[0069] 16. The modified LGIC of embodiment 4, wherein the α7-nAChR LBD comprises an L131M amino acid substitution and a Y115F amino acid substitution.

[0070] 17. The modified LGIC of embodiment 4, wherein the α7-nAChR LBD comprises a W77F amino acid substitution, a Q79G amino acid substitution, and a G175K amino acid substitution.

[0071] 18. The modified LGIC of embodiment 4, wherein the α7-nAChR LBD comprises a Q79G amino acid substitution, a Y115F amino acid substitution, and a G175K amino acid substitution.

[0072] 19. The modified LGIC of embodiment 4, wherein the α7-nAChR LBD comprises a Y115F amino acid substitution and a G175K amino acid substitution.

[0073] 20. The modified LGIC of embodiment 4, wherein the α7-nAChR LBD comprises a Q79G amino acid substitution and a 216I amino acid substitution.

[0074] 21. The modified LGIC of embodiment 1, wherein the IPD is an IPD from a receptor selected from the group consisting of a serotonin 3 receptor (5HT3) IPD, a glycine receptor (GlyR) IPD, a γ-aminobutyric acid (GABA) receptor IPD, and an α7 nicotinic acetylcholine receptor (α7-nAChR) IPD.

[0075] 22. The modified LGIC of embodiment 21, wherein the IPD comprises an amino acid substitution at residue 298.

[0076] 23. The modified LGIC of embodiment 22, wherein the IPD is a GlyR IPD, and wherein the amino acid substitution is an A298G substitution.

[0077] 24. The modified LGIC of embodiment 22, wherein the IPD is a GABA IPD, and wherein the amino acid substitution is a W298A substitution.

[0078] 25. The modified LGIC of embodiment 1, wherein an exogenous LGIC ligand activates the modified LGIC, and wherein the exogenous LGIC ligand is a synthetic exogenous LGIC ligand selected from the group consisting of quinuclidine, tropane, 9-azabicyclo[3.3.1]nonane, 6,7,8,9-tetrahydro-6,10-bridged methylene-6H-pyrazino(2,3-h)benzazepine and 1,4-diazabicyclo[3.2.2]nonane.

[0079] 26. The modified LGIC of embodiment 25, wherein the synthetic exogenous LGIC ligand is tropane, and wherein the tropane is selected from the group consisting of tropisetron, pseudotropisetron, nortropisetron, Compound 723, Compound 725, Compound 737, and Compound 745.

[0080] 27. The modified LGIC of embodiment 25, wherein the synthetic exogenous LGIC ligand is quinuclidine, wherein the quinuclidine is selected from the following group: PNU-282987, PHA-543613, compound 0456, compound 0434, compound 0436, compound 0354, compound 0353, compound 0295, compound 0296, compound 0536, compound 0676 and compound 702.

[0081] 28. The modified LGIC of embodiment 25, wherein the synthetic exogenous LGIC ligand is 9-azabicyclo[3.3.1]nonane, and wherein the 9-azabicyclo[3.3.1]nonane is compound 536.

[0082] 29. The modified LGIC of embodiment 25, wherein the synthesized exogenous LGIC ligand is 6,7,8,9-tetrahydro-6,10-methano-6H-pyrazino(2,3-h)benzazepine, and wherein the 6,7,8,9-tetrahydro-6,10-methano-6H-pyrazino(2,3-h)benzazepine is selected from the group consisting of varenicline, compound 765, and compound 770.

[0083] 30. The modified LGIC of embodiment 25, wherein the synthesized exogenous LGIC ligand is 1,4-diazabicyclo[3.2.2]nonane, and wherein the 1,4-diazabicyclo[3.2.2]nonane is selected from the group consisting of 3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)dibenzo[b,d]thiophene 5,5-dioxide, Compound 773, and Compound 774.

[0084] 31. The modified LGIC of embodiment 1, wherein the LBD is an α7-nAChR LBD, and wherein the α7-nAChR LBD further comprises at least one modified amino acid that confers selective binding to another α7-nAChR LBD having the at least one modified amino acid relative to binding to an unmodified LGIC.

[0085] 32. The modified LGIC of embodiment 31, wherein the unmodified LGIC is an endogenous LGIC.

[0086] 33. The modified LGIC of embodiment 32, wherein the endogenous LGIC is an endogenous α7-nAChR.

[0087] 34. The modified LGIC of embodiment 31, wherein the at least one modified amino acid that confers selective binding comprises an amino acid substitution at an amino acid residue at residue 27 and / or residue 41 of the α7-nAChR LBD.

[0088] 35. The modified LGIC of embodiment 34, wherein the at least one modified amino acid comprises an R27D substitution and / or an E41R substitution.

[0089] 36. The modified LGIC of embodiment 1, wherein the IPD is a murine 5HT3 IPD, and wherein the murine 5HT3 IPD further comprises at least one modified amino acid that confers increased ionic conductance to the modified LGIC.

[0090] 37. The modified LGIC of embodiment 36, wherein at least one modified amino acid in the mouse 5HT3 IPD that confers increased ionic conductance to the modified LGIC comprises an amino acid substitution at an amino acid residue at residue 425, 429 and / or 433 of the mouse 5HT3 IPD.

[0091] 38. The modified LGIC of embodiment 37, wherein the at least one modified amino acid comprises a R425Q substitution, a R429D substitution and / or a R433A substitution.

[0092] 39. The modified LGIC of embodiment 1, wherein the IPD is a human 5HT3 IPD, and wherein the human 5HT3 IPD further comprises at least one modified amino acid that confers increased ionic conductance to the modified LGIC.

[0093] 40. The modified LGIC of embodiment 39, wherein the at least one modified amino acid in the human 5HT3 IPD that confers increased ionic conductance to the modified LGIC comprises an amino acid substitution at an amino acid residue at residue 420, 424 and / or 428 of the human 5HT3 IPD.

[0094] 41. The modified LGIC of embodiment 40, wherein the at least one modified amino acid comprises a R420Q substitution, a R424D substitution and / or a R428A substitution.

[0095] 42. The modified LGIC of embodiment 1, wherein the LBD has reduced binding to endogenous LGIC ligands.

[0096] 43. The modified LGIC of embodiment 42, wherein the endogenous LGIC ligand is acetylcholine (ACh).

[0097] 44. The modified LGIC of embodiment 43, wherein the modified LGIC has an EC50 for ACh greater than 20 μM.

[0098] 45. A ligand having increased potency on a modified ligand-gated ion channel (LGIC), wherein the ligand comprises Formula I:

[0099]

[0100] wherein X1, X2 and X3 are each independently CH, CH2, O, NH or NMe;

[0101] Wherein each n is independently 0 or 1;

[0102] Where Y = O or S;

[0103] wherein A = an aromatic substituent; and

[0104] Wherein R=H or pyridylmethylene.

[0105] 46. ​​The ligand of embodiment 45, wherein the aromatic substituent is selected from the group consisting of 1H-indole, 4-(trifluoromethyl)benzene, 2,5-dimethoxybenzene, 4-chloroaniline, aniline, 5-(trifluoromethyl)pyridin-2-yl, 6-(trifluoromethyl)nicotine, and 4-chloro-benzene.

[0106] 47. The ligand of embodiment 45, wherein the ligand is a quinuclidine having formula II:

[0107]

[0108] Wherein X3=O, NH or CH2;

[0109] Where Y = O or S;

[0110] wherein A = an aromatic substituent; and

[0111] Wherein R=H or pyridylmethylene.

[0112] 48. The ligand of embodiment 47, wherein the aromatic substituent is selected from the group consisting of 1H-indole, 4-(trifluoromethyl)benzene, 4-chlorobenzene, 2,5-dimethoxybenzene, 4-(trifluoromethyl)benzene, 4-chloroaniline, aniline, 5-(trifluoromethyl)pyridin-2-yl, 6-(trifluoromethyl)nicotine, 3-chloro-4-fluorobenzene, and 1H-indole.

[0113] 49. The ligand of embodiment 47, wherein the quinuclidine is selected from the group consisting of PNU-282987, PHA-543613, Compound 0456, Compound 0434, Compound 0436, Compound 0354, Compound 0353, Compound 0295, Compound 0296, Compound 0536, Compound 0676, and Compound 702.

[0114] 50. The ligand of embodiment 45, wherein the ligand is a tropane having formula III:

[0115]

[0116] Where X2 = NH or NMe;

[0117] Wherein X3=O, NH or CH2;

[0118] Where Y = O or S; and

[0119] Where A = aromatic substituent.

[0120] 51. The ligand of embodiment 50, wherein the aromatic substituent is selected from the group consisting of 1H-indole, 1H-indazole, 7-methoxy-1H-indole, 7-methyl-1H-indole and 5-chloro-1H-indole.

[0121] 52. The ligand of embodiment 50, wherein the tropane is selected from the group consisting of tropisetron, pseudotropisetron, nortropisetron, Compound 723, Compound 725, Compound 737, and Compound 745.

[0122] 53. The ligand of embodiment 45, wherein the ligand is 9-azabicyclo[3.3.1]nonane having formula IV:

[0123]

[0124] Where X2 = NH or NMe;

[0125] Wherein X3=O, NH or CH;

[0126] Where Y = O or S; and

[0127] Where A = aromatic substituent.

[0128] 54. The ligand of embodiment 53, wherein the aromatic substituent is selected from the group consisting of 4-chloro-benzene, 1H-indole, 1H-indazole, 7-methoxy-1H-indazole.

[0129] 55. The ligand of embodiment 54, wherein the 9-azabicyclo[3.3.1]nonane is selected from the group consisting of Compound 0536, Compound 0749, Compound 0751, Compound 0760 and Compound 0763.

[0130] 56. A ligand having increased potency on a modified ligand-gated ion channel (LGIC), wherein the ligand comprises Formula V:

[0131]

[0132] wherein R1=H, phenyl, 2-toluoyl; 3-pyridyl; 4-pyridyl; trifluoromethyl; methoxy; ethoxy; propoxy, isopropoxy; N,N-dimethylamino; N,N-diethylamino; imidazole, pyrrole, pyrazole, triazole, or isoxazol-3-amine; and

[0133] Wherein R2=H, methyl or phenyl.

[0134] 57. The ligand of embodiment 56, wherein 6,7,8,9-tetrahydro-6,10-methano-6H-pyrazino(2,3-h)benzazepine is selected from the following group: Compound 0765, Compound 0770, Compound 0780, Compound 0782, Compound 0785, Compound 0788, Compound 0782, Compound 0789, Compound 0791, Compound 0793, Compound 0794, Compound 0795, Compound 0798, Compound 0799, Compound 0800, Compound 0801, Compound 0802, Compound 0803, Compound 0804, Compound 0805, Compound 0807, Compound 0808, Compound 0812, Compound 0813, Compound 815, Compound 816, and Compound 817.

[0135] 58. A ligand having increased potency on a modified ligand-gated ion channel (LGIC), wherein the ligand comprises Formula VII:

[0136]

[0137] Wherein R=H, F or NO2.

[0138] 59. The ligand of embodiment 58, wherein 1,4-diazabicyclo[3.2.2]nonane is selected from the group consisting of 3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)dibenzo[b,d]thiophene 5,5-dioxide, Compound 0773, and Compound 0774.

[0139] 60. A method of treating a channelopathy in a mammal, the method comprising:

[0140] administering to cells in the mammal a modified ligand-gated ion channel (LGIC), wherein an exogenous LGIC ligand selectively binds to the modified LGIC, the modified LGIC comprising at least one modified LGIC subunit comprising:

[0141] a ligand binding domain comprising at least one modified amino acid, and

[0142] an ion pore domain; and

[0143] The exogenous ligand is administered to the mammal.

[0144] 61. The method of embodiment 60, wherein the channelopathy is selected from the group consisting of Bartter syndrome, Brugada syndrome, catecholamine-dependent ventricular tachycardia (CPVT), congenital hyperinsulinemia, cystic fibrosis, Dravet syndrome, paroxysmal ataxia, erythromelalgia, generalized epilepsy (e.g., with febrile seizures), familial hemiplegic migraine, fibromyalgia, hyperkalemic periodic paralysis, hypokalemic periodic paralysis, Lambert myasthenic syndrome, long QT syndrome (e.g., Romano-Ward syndrome), short QT syndrome, malignant hyperthermia, mucolipidosis type IV, myasthenia gravis, myotonia congenita, neuromyelitis optica, neuromyotonia, nonsyndromic deafness, paramyotonia congenita, retinitis pigmentosa, timothy syndrome, tinnitus, seizures, trigeminal neuralgia, and multiple sclerosis.

[0145] 62. A method for regulating ion transport across a cell membrane of a mammalian cell, the method comprising:

[0146] administering to the cell a modified ligand-gated ion channel (LGIC), wherein an exogenous LGIC ligand selectively binds to the modified LGIC, the modified LGIC comprising at least one modified LGIC subunit comprising:

[0147] a ligand binding domain comprising at least one modified amino acid, and

[0148] an ion pore domain; and

[0149] The exogenous ligand is administered to the mammal.

[0150] 63. The method of embodiment 62, wherein the modulation comprises activating ion transport.

[0151] 64. The method of embodiment 62, wherein the modulation comprises inhibiting ion transport.

[0152] 65. The method of embodiment 62, wherein the cell is selected from the group consisting of a neuron, a glial cell, a muscle cell, a stem cell, an endocrine cell, and an immune cell.

[0153] 66. The method of embodiment 62, wherein administering the modified LGIC to the cell comprises in vivo administration.

[0154] 67. The method of embodiment 62, wherein administering the modified LGIC to the cell comprises ex vivo administration.

[0155] 68. A method of regulating cellular excitability in a mammal, the method comprising:

[0156] administering to the cell a modified ligand-gated ion channel (LGIC), wherein an exogenous LGIC ligand selectively binds to the modified LGIC, the modified LGIC comprising at least one modified LGIC subunit comprising:

[0157] a ligand binding domain comprising at least one modified amino acid, and

[0158] an ion pore domain; and

[0159] The exogenous ligand is administered to the mammal.

[0160] 69. The method of embodiment 68, wherein the modulation comprises increasing the excitability of the cells.

[0161] 70. The method of embodiment 68, wherein the modulation comprises reducing the excitability of the cell.

[0162] 71. The method of embodiment 68, wherein the cell is an excitable cell.

[0163] 72. The method of embodiment 68, wherein the cells are selected from the group consisting of neurons, glial cells, muscle cells, stem cells, endocrine cells, and immune cells.

[0164] 73. The method of embodiment 68, wherein administering the modified LGIC to the cell comprises in vivo administration.

[0165] 74. The method of embodiment 68, wherein administering the modified LGIC to the cell comprises ex vivo administration.

[0166] 75. A method of modulating cellular activity in a mammal, the method comprising:

[0167] administering to the cell a modified ligand-gated ion channel (LGIC), wherein an exogenous LGIC ligand selectively binds to the modified LGIC, the modified LGIC comprising at least one modified LGIC subunit comprising:

[0168] a ligand binding domain comprising at least one modified amino acid, and

[0169] an ion pore domain; and

[0170] The exogenous ligand is administered to the mammal.

[0171] 76. The method of embodiment 75, wherein the modulation comprises increasing the activity of the cell.

[0172] 77. The method of embodiment 75, wherein the modulation comprises reducing the activity of the cell.

[0173] 78. The method of embodiment 75, wherein the activity is selected from the group consisting of ion transport, passive transport, excitation, inhibition, and exocytosis.

[0174] 79. The method of embodiment 75, wherein the cells are selected from the group consisting of neurons, glial cells, muscle cells, stem cells, endocrine cells, and immune cells.

[0175] 80. The method of embodiment 75, wherein administering the modified LGIC to cells from the mammal comprises administering in vivo.

[0176] 81. The method of embodiment 75, wherein administering the modified LGIC to cells from the mammal comprises ex vivo administration.

[0177] 82. The method of any one of embodiments 60, 62, 68 or 75, wherein the modified LGIC is a chimeric LGIC comprising an LBD from a first LGIC and an IPD from a second LGIC.

[0178] 83. The method of embodiment 82, wherein the chimeric LGIC is a homomeric chimeric LGIC.

[0179] 84. The method of any one of embodiments 60, 62, 68 or 75, wherein administering the modified LGIC to the cell comprises administering a nucleic acid encoding the modified LGIC.

[0180] 85. The method of embodiment 84, wherein the modified LGIC comprises a sequence that is at least 85% identical to SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 or SEQ ID NO:10.

[0181] 86. The method of embodiment 85, wherein the modified LGIC comprises a sequence that is at least 90% identical to SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 or SEQ ID NO:10.

[0182] 87. The method of embodiment 86, wherein the modified LGIC comprises a sequence that is at least 95% identical to SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10.

[0183] 88. The method according to embodiment 87, wherein the modified LGIC comprises the sequence shown in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, or SEQ ID NO:10.

[0184] 89. The method of any one of embodiments 60, 62, 68 or 75, wherein the LBD is an α7 nicotinic acetylcholine receptor (α7-nAChR) LBD.

[0185] 90. The method of embodiment 89, wherein the at least one modified amino acid in the α7-nAChR LBD comprises at least one amino acid substitution at an amino acid residue selected from the group consisting of residues 77, 79, 115, 131, 139, 141, 175, 210, 216, 217 and 219 of the α7-nAChR LBD.

[0186] 91. The method of embodiment 90, wherein the amino acid substitution is at residue 77 of the α7-nAChR LBD, and wherein the amino acid substitution is selected from the group consisting of W77F and W77Y.

[0187] 92. The method of embodiment 90, wherein the amino acid substitution is at residue 79 of the α7-nAChR LBD, and wherein the amino acid substitution is selected from the group consisting of Q79A, Q79G, and Q79S.

[0188] 93. The method of embodiment 90, wherein the amino acid substitution is at residue 115 of the α7-nAChR LBD, and wherein the amino acid substitution is a Y115F substitution.

[0189] 94. The method of embodiment 90, wherein the amino acid substitution is at residue 131 of the α7-nAChR LBD, and wherein the amino acid substitution is selected from the group consisting of L131A, L131G, L131M and L131N.

[0190] 95. The method of embodiment 90, wherein the amino acid substitution is at residue 139 of the α7-nAChR LBD, and wherein the amino acid substitution is a Q139G or Q139L substitution.

[0191] 96. The method of embodiment 90, wherein the amino acid substitution is at residue 175 of the α7-nAChR LBD, and wherein the amino acid substitution is selected from the group consisting of G175A, G175F, G175H, G175K, G175M, G175R, G175S and G175V.

[0192] 97. The method of embodiment 90, wherein the amino acid substitution is at residue 210 of the α7-nAChR LBD, and wherein the amino acid substitution is a Y210F substitution.

[0193] 98. The method of embodiment 90, wherein the amino acid substitution is at residue 216 of the α7-nAChR LBD, and wherein the amino acid substitution is P216I.

[0194] 99. The method of embodiment 90, wherein the amino acid substitution is at residue 217 of the α7-nAChR LBD, and wherein the amino acid substitution is Y217F.

[0195] 100. The method of embodiment 90, wherein the amino acid substitution is at residue 219 of the α7-nAChR LBD, and wherein the amino acid substitution is D219A.

[0196] 101. The method of any one of embodiments 60, 62, 68 or 75, wherein the IPD comprises at least one modified amino acid.

[0197] 102. The method of embodiment 101, wherein the IPD is selected from the group consisting of a serotonin 3 receptor (5HT3) IPD, a glycine receptor (GlyR) IPD, a GABA receptor IPD, and an α7 nicotinic acetylcholine receptor (α7-nAChR) IPD.

[0198] 103. The method of embodiment 102, wherein the IPD is a GlyR IPD, and wherein the at least one modified amino acid comprises an amino acid substitution at residue 298 of the modified LGIC.

[0199] 104. The method of embodiment 103, wherein the amino acid substitution at residue 298 of the modified LGIC is an A298G substitution.

[0200] 105. The method of embodiment 102, wherein the IPD is GABA IPD, and wherein the at least one modified amino acid in the GABA IPD comprises an amino acid substitution at residue 298 of the modified LGIC.

[0201] 106. The method of embodiment 105, wherein the amino acid substitution at residue 298 of the chimeric LGIC is a W298A substitution.

[0202] 107. The method of any one of embodiments 60, 62, 68 or 75, wherein the exogenous LGIC ligand is a synthetic exogenous LGIC ligand.

[0203] 108. The method of embodiment 107, wherein the synthetic exogenous LGIC ligand is selected from the group consisting of tropane, quinuclidine, 9-azabicyclo[3.3.1]nonane, 1,4-diazabicyclo[3.2.2]nonane and 6,7,8,9-tetrahydro-6,10-methano-6H-pyrazino(2,3-h)benzazepine.

[0204] 109. The method of embodiment 108, wherein the synthetic exogenous LGIC ligand is tropane, and wherein the tropane is selected from the group consisting of tropisetron, pseudotropisetron, nortropisetron, Compound 723, Compound 725, Compound 737, and Compound 745.

[0205] 110. The method of embodiment 108, wherein the synthetic exogenous LGIC ligand is quinuclidine, and wherein the quinuclidine is selected from the group consisting of PNU-282987, PHA-543613, compound 0456, compound 0434, compound 0436, compound 0354, compound 0353, compound 0295, compound 0296, compound 0536, compound 0676 and compound 702.

[0206] 111. The method of embodiment 108, wherein the synthesized exogenous LGIC ligand is 9-azabicyclo[3.3.1]nonane, and wherein the 9-azabicyclo[3.3.1]nonane is selected from the group consisting of Compound 0536, Compound 0749, Compound 0751, Compound 0760, and Compound 0763.

[0207] 112. The method of embodiment 108, wherein the synthesized exogenous LGIC ligand is 1,4-diazabicyclo[3.2.2]nonane, and wherein the 1,4-diazabicyclo[3.2.2]nonane is selected from the group consisting of 3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)dibenzo[b,d]thiophene 5,5-dioxide, Compound 0773, and Compound 0774.

[0208] 113. The method of embodiment 108, wherein the synthesized exogenous LGIC ligand is 6,7,8,9-tetrahydro-6,10-methano-6H-pyrazino(2,3-h)benzazepine, and wherein the 6,7,8,9-tetrahydro-6,10-methano-6H-pyrazino(2,3-h)benzazepine is selected from the group consisting of varenicline, compound 0765 and compound 0770.

[0209] 114. A method for identifying a ligand that selectively binds to a modified ligand-gated ion channel (LGIC), the method comprising:

[0210] providing one or more candidate ligands to the modified LGIC of embodiment 1; and

[0211] Binding between the candidate ligand and the modified LGIC is detected, thereby identifying a ligand that selectively binds to the modified LGIC.

[0212] 115. The method of embodiment 114, wherein the modified LGIC is a chimeric LGIC comprising an LBD from a first LGIC and an IPD from a second LGIC.

[0213] 116. A method of detecting a modified ligand-gated ion channel (LGIC) comprising at least one modified LGIC subunit, the method comprising:

[0214] Providing one or more modified LGIC subunits of embodiment 1;

[0215] providing a reagent that selectively binds to the modified LGIC; and

[0216] The binding between the modified LGIC and the agent that selectively binds to the modified LGIC is detected, thereby detecting the modified LGIC.

[0217] 117. The method of embodiment 116, wherein the agent that selectively binds to the modified LGIC comprises an antibody, a protein, or a small molecule.

[0218] 118. The method of embodiment 117, wherein the agent that selectively binds to the modified LGIC comprises a detectable label.

[0219] 119. The method of embodiment 118, wherein the detectable label comprises a label selected from the group consisting of a fluorescent label, a radioactive label, and a positron emitting label.

[0220] 120. A mammalian cell comprising the modified LGIC of embodiment 1.

[0221] 121. A nucleic acid expressing the modified LGIC subunit of embodiment 1.

[0222] 122. A homomeric chimeric ligand-gated ion channel (LGIC), comprising chimeric LGIC subunits, each chimeric LGIC subunit comprising:

[0223] an alpha 7 nicotinic acetylcholine receptor ligand binding domain having a Q79G amino acid substitution and at least one of a W77F amino acid substitution, a Q139G amino acid substitution, a Y115F amino acid substitution, a G175K amino acid substitution, a Y210F amino acid substitution, a P216I amino acid substitution, a R27D amino acid substitution, and an E41R amino acid substitution; and

[0224] glycine receptor ion pore domain;

[0225] wherein a ligand selected from the group consisting of tropisetron and granisetron selectively binds to the chimeric LGIC, and wherein the chimeric LGIC minimally binds acetylcholine (ACh).

[0226] 123. A homomeric chimeric ligand-gated ion channel (LGIC), comprising chimeric LGIC subunits, each chimeric LGIC subunit comprising:

[0227] an alpha 7 nicotinic acetylcholine receptor ligand binding domain having an L131G amino acid substitution and at least one of a Q79S amino acid substitution, a Q139L amino acid substitution, a Y217F amino acid substitution, an R27D amino acid substitution, and an E41R amino acid substitution; and

[0228] an ion pore domain selected from the group consisting of a glycine receptor ion pore domain and a serotonin 3 receptor ion pore domain;

[0229] wherein a ligand selected from varenicline and tropisetron selectively binds to the chimeric LGIC, and wherein the chimeric LGIC minimally binds acetylcholine (ACh).

[0230] 124. A method of treating a channelopathy in a mammal, the method comprising:

[0231] administering the LGIC of embodiment 122 or embodiment 123 to cells in the mammal; and

[0232] The ligand is administered to the mammal.

[0233] 125. A method for regulating cellular excitability in a mammal, the method comprising:

[0234] administering the LGIC of embodiment 122 or embodiment 123 to cells in the mammal; and

[0235] The ligand is administered to the mammal.

[0236] 126. A method of modulating cellular activity in a mammal, the method comprising:

[0237] administering the LGIC of embodiment 122 or embodiment 123 to cells in the mammal; and

[0238] The ligand is administered to the mammal.

[0239] 127. A ligand having increased potency on a modified ligand-gated ion channel (LGIC), wherein the ligand comprises Formula VI:

[0240]

[0241] Wherein R1=H or CH3;

[0242] wherein R2=H, CH3 or an aromatic substituent; and

[0243] Wherein R3=O or S.

[0244] 128. The ligand of embodiment 127, wherein 7,8,9,10-tetrahydro-1H-6,10-methanoazepine[4,5-g]quinoxalin-2(6H)-one is selected from the group consisting of Compound 0783, Compound 0784, Compound 0790 and Compound 0792.

[0245] 129. A ligand having increased potency for a modified ligand-gated ion channel (LGIC), wherein the ligand comprises 2-(pyridin-3-yl)-1,5,6,7,8,9-hexahydro-5,9-methanoimidazo[4',5':4,5]benzo[1,2-d]azepine (Compound 0786):

[0246]

[0247] 130. The modified LGIC of embodiment 15, wherein the modified LGIC further comprises an endoplasmic reticulum export sequence.

[0248] 131. The modified LGIC of embodiment 130, wherein the endoplasmic reticulum export sequence comprises the amino acid sequence FCYENEV (SEQ ID NO: 16).

[0249] 132. The modified LGIC of embodiment 131, wherein the modified LGIC comprises the amino acid sequence shown in SEQ ID NO:13.

[0250] 133. The modified LGIC of embodiment 15, wherein the modified LGIC further comprises a CHRNB4 signal sequence.

[0251] 134. A modified LGIC of embodiment 133, wherein the CHRNB4 signal sequence comprises the amino acid sequence MRRAPSLVLFFLVALCGRGNC (SEQ ID NO: 17).

[0252] 135. The modified LGIC of embodiment 134, wherein the modified LGIC comprises the amino acid sequence shown in SEQ ID NO:14.

[0253] 136. The modified LGIC of embodiment 15, wherein the modified LGIC further comprises a KCNB1 somatic targeting sequence.

[0254] 137. The modified LGIC of embodiment 136, wherein the KCNB1 somatic targeting sequence comprises the amino acid sequence QSQPILNTKEMAPQSKPPEELEMSSMPSPVAPLPARTEGVIDMRSMSSIDSFISCATDFPEATRF (SEQ ID NO: 18).

[0255] 138. The modified LGIC of embodiment 137, wherein the modified LGIC comprises the amino acid sequence shown in SEQ ID NO:15.

[0256] 139. A synthetic nucleic acid construct comprising a nucleic acid sequence having at least 75% sequence identity to the sequence shown in SEQ ID NO:27.

[0257] 140. The synthetic nucleic acid construct of embodiment 139, wherein the nucleic acid sequence having at least 75% sequence identity with the sequence shown in SEQ ID NO: 27 comprises a nucleic acid sequence encoding a ligand binding domain (LBD) comprising an amino acid modification.

[0258] 141. The synthetic nucleic acid construct of embodiment 140, wherein the LBD is an α7 nicotinic acetylcholine receptor (α7-nAChR) LBD, and wherein the modified LBD comprises an amino acid substitution at one or more amino acid residues selected from the group consisting of residues 77, 79, 115, 131, 139, 141, 175, 210, 216, 217 and 219 of the α7-nAChR LBD.

[0259] 142. The synthetic nucleic acid construct of embodiment 139, wherein the nucleic acid sequence having at least 75% sequence identity with the sequence shown in SEQ ID NO: 27 comprises a nucleic acid sequence encoding an ion pore domain (IPD).

[0260] 143. The synthetic nucleic acid construct of embodiment 142, wherein the IPD is an IPD from a receptor selected from the group consisting of a serotonin 3 receptor (5HT3) IPD, a glycine receptor (GlyR) IPD, a gamma-aminobutyric acid (GABA) receptor IPD, and an α7 nicotinic acetylcholine receptor (α7-nAChR) IPD.

[0261] 144. The synthetic nucleic acid construct of embodiment 143, wherein the IPD is a 5HT3 IPD.

[0262] 145. A synthetic nucleic acid construct comprising a nucleic acid sequence having at least 75% sequence identity to the sequence shown in SEQ ID NO:28.

[0263] 146. The synthetic nucleic acid construct of embodiment 145, wherein the nucleic acid sequence having at least 75% sequence identity with the sequence shown in SEQ ID NO: 28 comprises a nucleic acid sequence encoding a ligand binding domain (LBD) comprising an amino acid modification.

[0264] 147. The synthetic nucleic acid construct of embodiment 146, wherein the LBD is an α7 nicotinic acetylcholine receptor (α7-nAChR) LBD, and wherein the modified LBD comprises an amino acid substitution at one or more amino acid residues selected from the group consisting of residues 77, 79, 115, 131, 139, 141, 175, 210, 216, 217 and 219 of the α7-nAChR LBD.

[0265] 148. The synthetic nucleic acid construct of embodiment 145, wherein the nucleic acid sequence having at least 75% sequence identity with the sequence shown in SEQ ID NO: 28 comprises a nucleic acid sequence encoding an ion pore domain (IPD).

[0266] 149. The synthetic nucleic acid construct of embodiment 148, wherein the IPD is an IPD from a receptor selected from the group consisting of a serotonin 3 receptor (5HT3) IPD, a glycine receptor (GlyR) IPD, a gamma-aminobutyric acid (GABA) receptor IPD, and an α7 nicotinic acetylcholine receptor (α7-nAChR) IPD.

[0267] 150. The synthetic nucleic acid construct of embodiment 149, wherein the IPD is a GlyR IPD, and wherein the GlyRIPD comprises an amino acid modification.

[0268] 151. The synthetic nucleic acid construct of embodiment 150, wherein the modified GlyR IPD comprises an amino acid substitution at amino acid residue 298 of GlyR IPD.

[0269] 152. A synthetic nucleic acid construct comprising a nucleic acid sequence having at least 75% sequence identity to the sequence shown in SEQ ID NO:29.

[0270] 153. The synthetic nucleic acid construct of embodiment 152, wherein the nucleic acid sequence having at least 75% sequence identity with the sequence shown in SEQ ID NO:29 comprises a nucleic acid sequence encoding a ligand binding domain (LBD) comprising an amino acid modification.

[0271] 154. The synthetic nucleic acid construct of embodiment 153, wherein the LBD is an α7 nicotinic acetylcholine receptor (α7-nAChR) LBD, and wherein the modified LBD comprises an amino acid substitution at one or more amino acid residues selected from the group consisting of residues 77, 79, 115, 131, 139, 141, 175, 210, 216, 217 and 219 of the α7-nAChR LBD.

[0272] 155. The synthetic nucleic acid construct of embodiment 152, wherein the nucleic acid sequence having at least 75% sequence identity with the sequence shown in SEQ ID NO:29 comprises a nucleic acid sequence encoding an ion pore domain (IPD).

[0273] 156. The synthetic nucleic acid construct of embodiment 155, wherein the IPD is an IPD from a receptor selected from the group consisting of a serotonin 3 receptor (5HT3) IPD, a glycine receptor (GlyR) IPD, a gamma-aminobutyric acid (GABA) receptor IPD, and an α7 nicotinic acetylcholine receptor (α7-nAChR) IPD.

[0274] 157. The synthetic nucleic acid construct of embodiment 156, wherein the IPD is GABA IPD, and wherein the GABA IPD comprises an amino acid modification.

[0275] 158. The synthetic nucleic acid construct of embodiment 157, wherein the modified GABA IPD comprises an amino acid substitution at amino acid residue 298 of GABA IPD.

[0276] 159. A synthetic nucleic acid construct comprising the sequence shown in SEQ ID NO:33.

[0277] 160. A synthetic nucleic acid construct comprising the sequence shown in SEQ ID NO:34.

[0278] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those of ordinary skill in the art to which the present disclosure belongs. Methods and materials for use in the present disclosure are described herein; other suitable methods and materials known in the art may also be used. The materials, methods, and examples are illustrative only and not limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In the event of a conflict, the present specification (including definitions) shall prevail.

[0279] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0281] Figures 1A-1E Shown are exemplary amino acid sequences of chimeric LGICs. Mutations of amino acid residue 77 (e.g., W77F or W77Y) result in sensitivity to granisetron and tropisetron. Mutations of amino acid residue 79 (e.g., Q79G) are most effective for several agonists. Mutations of amino acid residue 131 (e.g., L131G, L131A, L131M, or L131N) change sensitivity to varenicline, tropisetron, granisetron, and ACh. When LBD mutations are combined with mutations at amino acid residue 298 in GlyR or GABAc IPD, efficacy is substantially enhanced. When α7nAChR LBD mutations are combined with mutations at amino acid residues G175 and P216, efficacy is also enhanced. A) Amino acid sequence of α7-5HT3 chimeric receptor (SEQ ID NO:6), including human α7nAChRLBD (SEQ ID NO:1) and mouse 5HT3 IPD (SEQ ID NO:3) components. B) Amino acid sequence of the α7-GlyR chimeric receptor (SEQ ID NO:7), including human α7nAChR LBD (SEQ ID NO:2) and human GlyR IPD (SEQ ID NO:5) components. C) Amino acid sequence of the α7-5HT3 chimeric receptor (SEQ ID NO:8), including human α7nAChR LBD (SEQ ID NO:1) and human 5HT3 IPD (SEQ ID NO:4) components. D) Amino acid sequence of the α7-GABAc chimeric receptor (SEQ ID NO:10), including human α7nAChR LBD (SEQ ID NO:11) and human GABAc IPD (SEQ ID NO:9) components. E) Amino acid sequence of the rat nAChR sequence (SEQ ID NO:12).

[0282] Figure 2The effects of tropisetron on α7-5HT3 chimeric LGIC and Figures 1A-1E EC50 of variants of chimeric LGICs with LBD mutations at the indicated positions. Multiple mutations at Gln79 showed similar or improved potency relative to unmodified α7-5HT3 channels (arrows).

[0283] Figure 3A-3B The relative potency of known nAChR agonists on α7-5HT3 chimeric LGICs is shown. A) Plot of EC50 normalized to unmodified α7-5HT3 chimeric channels (logarithmic scale). *P<0.05, statistically significant potency changes noted (ANOVA followed by Dunn's test). B) Chemical structures of known nAChR agonists.

[0284] Figures 4A-4C The relative potency of known nAChR agonists on α7-GlyR chimeric LGICs is shown. A) EC50 plot of the Q79 LBD mutant normalized to unmodified α7-GlyR chimeric channels (logarithmic scale). B) EC50 plot of the A298G IPD mutant normalized to unmodified α7-GlyR chimeric channels (logarithmic scale). C) EC50 plot of the A298G IPD mutant normalized to unmodified α7-GlyR chimeric channels and compared to the double mutant channels α7Q79G-GlyR A298G Comparison of α7-GlyR A298G EC50 graphs (logarithmic scale). *P<0.05, statistically significant change in potency noted (ANOVA followed by Dunn's test).

[0285] Figures 5A-5C Schematic structures of LGIC agonists with α7 Q79G -5HT3 and α7 Q79G -GlyR A298G The substitution patterns most compatible with potency enhancement of α7 are shown in Figure 2. A) Generic structures showing properties associated with potency enhancement. B) Specific pharmacophores shown in (A) are quinuclidine, tropane, and 9-azabicyclo[3.3.1]nonane core structures. C) Exemplary synthetic molecules that enhance α7 Q79G -GlyR A298G 、α7 Q79G,Y115F,G175K -GlyR, α7 W77F,Q79G,G175K -GlyR showed high potency.

[0286] Figures 6A-6C Mutations that reduce binding of the chimeric LCIGα7nAChR LBD to the unmodified LBD are shown. A) Transfection of two constructs encoding α7-5HT3 with epitope tags (HA and V5) (top) or two constructs encoding α7-5HT3-HA and α7R21D ,E41R Schematic diagram of charge reversal of the construct of α7-5HT3-V5, in which binding between two subunits with different epitope tags is unfavorable due to charge reversal mutations at the subunit interface. B) Schematic diagram of charge reversal of the construct of α7-5HT3-V5, in which binding between two subunits with different epitope tags is unfavorable due to charge reversal mutations at the subunit interface. R21D ,E41R Whole-cell recordings in HEK cells expressing α7-5HT3 show a robust response to PNU-282987. C) Binding of α7-5HT3 LGICs to HA and V5 epitope tags in HEK cells was probed by HA immunoprecipitation (left) or fractionation of total lysates followed by Western blotting with anti-HA (top) or anti-V5 antibodies (bottom). In cells co-expressing channels with HA and V5 epitopes, anti-HA IP followed by anti-V5 immunoblotting shows co-immunoprecipitation of each type of unmodified channel, but LBDα7 R21D,E41R -The charge reversal mutation in 5HT3-V5 was not immunoprecipitated. The MW of α7-5HT3 is approximately 48 kD (arrow).

[0287] Figure 7 showed that chimeric LGICs can be controlled using exogenous ligands. Q79G -GlyR A298G Cortical neurons of chimeric LGIC-transduced mouse brains fired action potentials in response to 40 pA current injection (PRE), which were potently inhibited by 30 nM tropisetron. Neuron firing was restored after washout of tropisetron (WASH).

[0288] Figures 8A-8C Activity of agonists on chimeric LGICs with the G175K mutation is shown. A) Plot of EC50 of the Q79G G175K LBD mutant against known agonists normalized to the unmodified α7-GlyR chimeric channel (logarithmic scale). B) Plot of EC50 of channels with mutations in α7-GlyR chimeric LGICs against ACh and tropisetron. Mutations that result in high potency for tropisetron and low potency for the endogenous ligand acetylcholine (ACh) are optimal (grey shading). Unmodified: Unmodified α7-GlyR chimeric LGIC. C) EC50 of the Q79G G175K LBD mutant against known agonists normalized to the unmodified α7-GlyR chimeric channel. Q79G,Y115F,G175K Action potentials of cortical neurons of mouse brain transduced with -GlyR chimeric LGICs. Neurons fired in response to current injection (PRE) and were potently inhibited by 100 nM tropisetron. Neuronal firing was restored after tropisetron washout (WASH).

[0289] Figures 9A-9EThe activity of agonists on chimeric LGICs with the L131G mutation is shown. A) Plot of the EC50 of L131 LBD mutants for known agonists normalized to the unmodified α7-GlyR chimeric channel (logarithmic scale). B) α7 L131G Graph showing the EC50 of channels with mutations in α7-GlyR chimeric LGICs for ACh and tropisetron. C) Graph showing that mutations resulting in high potency for varenicline and low potency for the endogenous ligand acetylcholine (ACh) are optimal (grey shading). Unmodified: Unmodified α7-GlyR chimeric LGIC. D) Graph showing activation of channels with mutations in α7L131G-GlyR after transient channel antagonism by picrotoxin (PTX). Solid lines represent the duration of molecule administration. E) Graph from α7 treated with α7 L131G,Q139L,Y217F Action potentials of cortical neurons of mouse brain transduced with -GlyR chimeric LGICs. Neurons fired in response to current injection (PRE) and were potently inhibited by 10 nM varenicline, even when the injected current was >6-fold greater. Neuronal firing was restored after varenicline (WASH).

[0290] Fig.10 The figure contains a graph showing that varenicline can activate chimeric receptors in mice to induce behavioral effects. In this case, α7 is expressed unilaterally in VGAT-expressing neurons in the substantia nigra reticulum. L131G,Q139L,Y217F -GlyR, followed by varenicline administration, resulted in contralateral rotation, which was consistent with varenicline-induced activation of α7 L131G,Q139L,Y217F -GlyR-expressing neurons were consistently silenced.

[0291] Figures 11A-11C The chemical structures of exemplary LGIC agonists are shown. A) has a Q79G,Y115F,G175K Chemical structures of LGIC agonists with substitution patterns most compatible with potency enhancement of -GlyR. L131G,Q139L,Y217F -GlyR, α7 L131G,Q139L,Y217F -5HT3 or α7 L131G,Q139L,Y217F Chemical structures of LGIC agonists with substitution patterns most compatible with potency enhancement of 5HT3 HC. L131G,Q139L,Y217F -GlyR or α7 L131G,Q139L,Y217F Chemical structures of LGIC agonists with the most compatible substitution patterns for potency enhancement of -5HT3 HC.

[0292] Figures 12A-12F Chemical genetic perturbations of cortical neuron activity are shown. A-B) Chemical genetic perturbations of cortical neuron activity in neurons expressing PSAM due to reduced input resistance (A) and increased basal strength (B) 4 Varenicline strongly inhibits action potential firing in neurons expressing -GlyR. C) Membrane properties of cortical layer 2 / 3 neurons in PSAM4 -GlyR-expressing neurons and mixed untransfected control neurons. 4 -5HT3HC depolarizes neurons (D) and triggers firing (E). F) Membrane properties of cortical layer 2 / 3 neurons in PSAM 4 -5HT3 HC expressing neurons and pooled untransfected control neurons were similar. Data are mean ± SEM. Mann Whitney U-test, nsP>0.05, ***P<0.001.

[0293] Figures 13A-13D PSAM in mice 4 -GlyR neuronal silencing. A) PSAM 4 -GlyR-IRES-EGFP unilaterally targeted to the SNr. Inset: Schematic representation of unilateral SNr transduction leading to silencing and contraversive rotation. Asterisk: nonspecific immunofluorescence. B) Low dose intraperitoneal varenicline induces expression of PSAM 4 -GlyR-expressing mice, but not sham-operated or EGFP-expressing mice. C) Two doses of varenicline separated by 5 h gave similar total rotation ratios, indicating rapid tolerance without chemogenetic response. D) Duration of chemogenetic silencing monitored by the time course of rotational response normalized to the maximum rotation of each mouse. Pink (narrow) arrow: amphetamine injection, cyan (wide) arrow: varenicline injection. Mann-Whitney U-test, nsP>0.05, **P<0.01.

[0294] Figures 14A-14J Ultra-potent chemical genetic agonists (uPSEMs) are shown. A) PSAM 4 uPSEM agonist EC50 at channels and endogenous varenicline targets, and comparison of IC50 against α4β2 nAChR at 1 μM Chl. LED: lowest effective dose in mice in SNr rotation assay. Units: nM; brackets: SEM. Bold relative to PSAM 4 -GlyR selectivity. B, C) PSAM 4 Dose response curves of -GlyR, α4β2nAChR, and 5HT3-R. uPSEM 792 (B) is a 10% partial agonist of α4β2 nAChR, and uPSEM 817(C) Inhibition of α4β2nAChR. D) Current responses to uPSEMs (2μM) and ACh (10μM) in HEK cells expressing α7nAChR. uPSEM does not activate α7nAChR, while ACh activates α7nAChR. (E) Response amplitude normalized to ACh. FJ) uPSEM 792 、uPSEM 793 、uPSEM 815 and uPSEM 817 Strongly inhibits PSAM expression by reducing the current required to fire action potentials (basal strength) 4 -GlyR firing in cortical neurons (GJ).

[0295] Figures 15A-15H Shows unilateral expression of PSAM in the SNr 4 In vivo uPSEM dose response in mice expressing -GlyR. 792 (A, B), uPSEM 793 (C, D), uPSEM 815 (E, F), uPSEM 817 (G,H) Behavioral responses and time course. Time course of rotational responses normalized to the maximum rotation of each mouse. Pink (narrow) arrows: amphetamine injection, blue (wide) arrows: uPSEM injection.

[0296] Fig.16 An exemplary amino acid sequence of PSAM4-GlyR-KirM3M4 (SEQ ID NO: 13) is shown. 4 Mutations are highlighted. The sequence of the Kir2.1 (KCNJ2) endoplasmic reticulum (ER) export sequence is underlined and blue.

[0297] Fig.17 PSAM is shown 4 -Exemplary amino acid sequence of GlyR-B4sig (SEQ ID NO: 14). PSAM 4 The mutation is highlighted. The sequence of the β4 nAChR subunit (CHRNB4) signal sequence is underlined and blue.

[0298] Fig.18 PSAM is shown 4 -Exemplary amino acid sequence of GlyR-Kv2M3M4-soma (SEQ ID NO: 15). PSAM 4 The mutation is highlighted. The sequence of the Kv2.1 (KCNB1) somatic targeting sequence is underlined and blue.

[0299] Figures 19A-19BExemplary constructs are shown, which contain nucleic acid sequences encoding modified LGIC subunits. (A) Plasmid map of the AAV-Syn::PSAM4-GlyR-IRES-EGFP-WPRE construct, which contains nucleic acid sequences encoding modified LGIC subunits (SEQ ID NO:33). (B) Nucleic acid sequence of the AAV-Syn::PSAM4-GlyR-IRES-EGFP-WPRE construct, which contains nucleic acid sequences encoding modified LGIC subunits.

[0300] Figures 20A-20B Exemplary constructs are shown, which contain nucleic acid sequences encoding modified LGIC subunits. (A) Plasmid map of the AAV-CamkII::PSAM4-GlyR-IRES-EGFP-WPRE construct, which contains nucleic acid sequences encoding modified LGIC subunits (SEQ ID NO:34). (B) Nucleic acid sequence of the AAV-CamkII::PSAM4-GlyR-IRES-EGFP-WPRE construct, which contains nucleic acid sequences encoding modified LGIC subunits. DETAILED DESCRIPTION OF THE INVENTION

[0302] This document provides modified LGICs and methods of using the same. For example, this document provides a modified LGIC comprising at least one modified LGIC subunit having an LBD and an IPD and having at least one modified amino acid (e.g., an amino acid substitution). In some cases, the modified LGIC may be a chimeric LGIC. For example, a chimeric LGIC may include an LBD from a first LGIC and an IPD from a second LGIC. In some cases, the modified amino acid may impart pharmacological selectivity to the modified LGIC. For example, the modified amino acid may impart selective binding of an exogenous LGIC ligand to the modified LGIC. For example, the modified amino acid may impart reduced (e.g., minimized or eliminated) binding to the modified LGIC relative to an unmodified LGIC subunit (e.g., a LGIC subunit lacking a modification and / or an endogenous LGIC subunit). For example, the modified amino acid may impart reduced (e.g., minimized or eliminated) binding of an endogenous LGIC ligand to the modified LGIC.

[0303] The modified LGICs provided herein can be used, for example, in methods for treating channelopathies (e.g., neural channelopathies or muscle channelopathies). For example, modified LGICs and exogenous LGIC ligands that can bind to and activate modified LGICs can be used to treat mammals suffering from channelopathies. In some cases, modified LGICs and exogenous LGIC ligands can be used to regulate (e.g., activate or inhibit) ion transport across mammalian cell membranes. In some cases, modified LGICs and exogenous LGIC ligands can be used to regulate (e.g., increase or decrease) the excitability of cells in mammals.

[0304] Modified LGIC

[0305] As used herein, a "modified" LGIC is a LGIC comprising at least one LGIC subunit. A modified LGIC may also be referred to as a pharmacologically selective actuator module (PSAM). A modified LGIC subunit may comprise at least one modified amino acid (e.g., amino acid substitution) in an LBD and / or at least one modified amino acid (e.g., amino acid substitution) in an IPD. The modified LGIC subunits described herein may be modifications of LGICs from any appropriate species (e.g., humans, rats, mice, dogs, cats, horses, cattle, goats, pigs, or monkeys). In some cases, a modified LGIC may include at least one chimeric LGIC subunit having a non-naturally occurring combination of an LBD from a first LGIC and an IPD from a second LGIC.

[0306] A modified LGIC (e.g., an LGIC comprising one or more modified LGIC subunits) can be homomeric (e.g., having any number of identical modified LGIC subunits) or heteromeric (e.g., having at least one modified LGIC subunit and any number of different LGIC subunits). In some cases, a modified LGIC described herein can be a homomeric modified LGIC. A modified LGIC described herein can include any suitable number of modified LGIC subunits. In some cases, a modified LGIC can be a trimer, a tetramer, a pentamer, or a hexamer. For example, a modified LGIC described herein can be a pentamer.

[0307] The modified LGIC subunits described herein can be modifications of any suitable LGIC. The LGIC can conduct anions, cations, or both across a cell membrane in response to the binding of a ligand. For example, the LGIC can transport sodium (Na+), potassium (K+), calcium (Ca 2+), and / or chloride (Cl-) ions across a cell membrane in response to the binding of a ligand. Examples of LGICs include, but are not limited to, Cys loop receptors (e.g., AChRs, such as nAChRs (e.g., muscle nAChRs or neuronal nAChRs), gamma-aminobutyric acid (GABA; e.g., GABA A and GABA A -ρ (also known as GABA C ) receptors, GlyR, GluCl receptors and 5HT3 receptors), ionotropic glutamate receptors (iGluR; such as AMPA receptors, kainate receptors, NMDA receptors and delta receptors), ATP-gated channels (such as P2X) and phosphatidylinositol 4,5-bisphosphate (PIP2)-gated channels. In the case where the modified LGIC described herein is a chimeric LGIC, the chimeric LGIC may include an LBD selected from any appropriate LGIC and an IPD selected from any appropriate LGIC. In the case where the LGIC includes multiple different subunits (e.g., neuronal nAChR includes α4, β2 and α7 subunits), the LBD and / or IPD can be selected from any subunit. For example, the LBD from a nAChR can be an α7LBD. A representative rat α7nAChR amino acid sequence (including both the LBD and the IPD) is as follows.

[0308] SEQ ID NO:12

[0309]

[0310] In some cases, the modified LGIC subunit described herein may include an LBD from an α7nAChR. Examples of α7nAChR LBDs include, but are not limited to, a human α7nAChR LBD having an amino acid sequence as shown in SEQ ID NO: 1, a human α7nAChR LBD having an amino acid sequence as shown in SEQ ID NO: 2, and a human α7nAChR LBD having an amino acid sequence as shown in SEQ ID NO: 11. In some cases, the α7nAChR LBD may be a homolog, an ortholog, or a paralog of the human α7nAChR LBD shown in SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 11. In some cases, the α7 nAChR LBD can have at least 75% sequence identity to SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:11 (e.g., at least 80%, at least 82%, at least 85%, at least 88%, at least 90%, at least 93%, at least 95%, at least 97%, or at least 99% sequence identity).

[0311] SEQ ID NO:1

[0312]

[0313] SEQ ID NO:2

[0314]

[0315] SEQ ID NO:11

[0316]

[0317] In some cases, the modified LGIC subunit described herein may include an IPD from a 5HT3 receptor. Examples of 5HT3 IPDs include, but are not limited to, mouse 5HT3 IPDs having an amino acid sequence as shown in SEQ ID NO: 3 and human 5HT3 IPDs having an amino acid sequence as shown in SEQ ID NO: 4. In some cases, the 5HT3 IPD may be a homolog, ortholog, or paralog of the 5HT3 IPD shown in SEQ ID NO: 3 or SEQ ID NO: 4. In some cases, the 5HT3 IPD may have at least 75% sequence identity (e.g., at least 80%, at least 82%, at least 85%, at least 88%, at least 90%, at least 93%, at least 95%, at least 97%, or at least 99% sequence identity) with SEQ ID NO: 3 or SEQ ID NO: 4.

[0318] SEQ ID NO:3

[0319]

[0320] SEQ ID NO:4

[0321]

[0322] In some cases, the modified LGIC subunit described herein may include an IPD from GlyR. Examples of GlyR IPDs include, but are not limited to, a mouse GlyR IPD having an amino acid sequence as shown in SEQ ID NO:5. In some cases, the GlyRIPD may be a homolog, a straight homolog, or a paralog of the human GlyR IPD shown in SEQ ID NO:5. In some cases, the GlyR IPD may have at least 75% sequence identity (e.g., at least 80%, at least 82%, at least 85%, at least 88%, at least 90%, at least 93%, at least 95%, at least 97%, or at least 99% sequence identity) with SEQ ID NO:5.

[0323] SEQ ID NO:5

[0324]

[0325] In some cases, the modified LGIC subunits described herein may include a GABA receptor (e.g., GABA A-ρ , also known as GABA C ) of IPD. GABA A-ρ Examples of IPD include, but are not limited to, human GABA having an amino acid sequence as shown in SEQ ID NO: 9. A-ρ IPD. In some cases, GABA A-ρ The IPD may be the human GABA shown in SEQ ID NO:9 A-ρ Homologs, orthologs, or paralogs of IPD. In some cases, GABA A-ρ The IPD may have at least 75% sequence identity to SEQ ID NO:9 (e.g., at least 80%, at least 82%, at least 85%, at least 88%, at least 90%, at least 93%, at least 95%, at least 97%, or at least 99% sequence identity).

[0326] SEQ ID NO:9

[0327]

[0328] In calculating the percentage of sequence identity, two sequences are compared and the number of identical matches of amino acid residues between the two sequences is determined. The number of identical matches is divided by the length of the comparison region (that is, the number of amino acid residues compared) and multiplied by 100 to obtain the percentage sequence identity value. It should be understood that the length of the comparison region can be a part of one or both sequences, up to the full-length size of the shortest sequence. It should also be understood that a single sequence can be compared with more than one other sequence, therefore, different percentage sequence identity values ​​can be provided on each comparison region. The comparison of two or more sequences can be performed using the computer program ClustalW and default parameters to determine the percentage of sequence identity, and the default parameters calculate the best match between the query and one or more subject sequences, and align them, so that identity, similarity and difference can be determined. See, for example, Chenna et al., 2003, Nucleic Acids Res., 31 (13): 3497-500.

[0329] In the case where the modified LGIC subunit described herein is a chimeric LGIC subunit, the chimeric LGIC subunit may include an LBD and an IPD from the same species or an LBD and an IPD from different species. In some cases, the chimeric LGIC subunit may include an LBD from a human LGIC protein and an IPD from a human LGIC protein. For example, a chimeric LGIC subunit may include a human α7 LBD and a human GlyR IPD. In some cases, a chimeric LGIC subunit may include an LBD from a human LGIC protein and an IPD from a mouse LGIC protein. For example, a chimeric LGIC subunit may include a human α7 LBD and a mouse 5HT3 IPD.

[0330] Where the modified LGIC subunits described herein are chimeric LGIC subunits, the chimeric LGIC subunits can include different fusion points connecting the LBD and the IPD, such that the number of amino acids in the LBD can vary when the LBD is fused to different IPDs to form chimeric channel subunits. For example, the length of the α7nAChR LBD used to form a chimeric LGIC subunit with a 5HTS IPD is different from the length of the α7nAChR LBD used to form a chimeric LGIC subunit with a GlyR IPD (e.g., compare Figure 1A and 1C and Figure 1B ).

[0331] The modified LGIC subunits described herein may include an LBD having at least one modified amino acid and / or an IPD having at least one modified amino acid. For example, the modified LGIC subunits described herein may include an α7 LBD having at least 75% sequence identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11, or SEQ ID NO: 12, and amino acid substitutions at amino acid residues 27, 41, 77, 79, 131, 139, 141, 175, 210, 216, 217, and / or 219. For example, the modified LGIC subunits described herein may include a GlyR IPD having at least 75% sequence identity to the sequence shown in SEQ ID NO: 5, and an amino acid substitution at amino acid residue 298 of an α7-GlyR chimeric receptor (e.g., SEQ ID NO: 7). For example, the modified LGIC subunits described herein may include GABA c IPD having at least 75% sequence identity to SEQ ID NO:9, and α7-GABA C Amino acid substitution at amino acid residue 298 of a chimeric receptor (e.g., SEQ ID NO: 10). In some cases, the modified LGIC subunit described herein may include more than one (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more) amino acid modifications. The modification may be an amino acid substitution. In some cases, the modified amino acid may confer pharmacological selectivity to the modified LGIC. For example, the modified amino acid may confer selective binding of an exogenous LGIC ligand to the modified LGIC. For example, the modified amino acid may confer reduced (minimized or eliminated) binding to the modified LGIC relative to an unmodified LGIC subunit (a LGIC subunit lacking a modified LGIC subunit and / or an endogenous LGIC subunit). For example, the modified amino acid may confer reduced (minimized or eliminated) binding of an endogenous LGIC ligand to the modified LGIC.

[0332] In some aspects, the modified LGIC subunit described herein may comprise at least one modified amino acid that imparts selective binding to an exogenous LGIC ligand (e.g., enhanced binding or increased potency) to the modified LGIC. Binding to an exogenous LGIC ligand may be selective relative to binding to an endogenous LGIC ligand. A modified LGIC subunit having selective binding to an exogenous LGIC ligand may include any suitable LDB (e.g., α7 LBD). In some aspects, the modified LGIC subunit may include the α7 LBD shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11, or SEQ ID NO: 12, and the amino acid modification may be a substitution at amino acid residues 77, 79, 131, 139, 141, 175, and / or 216. In some cases, the tryptophan at amino acid residue 77 of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11 or SEQ ID NO: 12 can be substituted with a hydrophobic amino acid residue, such as phenylalanine (e.g., W77F), tyrosine (e.g., W77Y) or methionine (e.g., W77M). For example, the modified LGIC subunit described herein can include an α7LBD shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11 or SEQ ID NO: 12 and having a W77F substitution. In some cases, the glutamine at amino acid residue 79 of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11 or SEQ ID NO: 12 can be substituted with an amino acid residue, such as alanine (e.g., Q79A), glycine (e.g., Q79G) or serine (e.g., Q79S). For example, the modified LGIC subunit described herein can include an α7LBD having a Q79G substitution. In some cases, the leucine at amino acid residue 131 of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11, or SEQ ID NO: 12 can be substituted with an amino acid residue such as alanine (e.g., L131A), glycine (e.g., L131G), methionine (e.g., L131M), asparagine (e.g., L131N), glutamine (e.g., L131Q), valine (e.g., L131V), or phenylalanine (e.g., L131F).In some cases, the glycine at amino acid residue 175 of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11 or SEQ ID NO: 12 can be substituted with an amino acid residue such as lysine (e.g., G175K), alanine (e.g., G175A), phenylalanine (e.g., G175F), histidine (e.g., G175H), methionine (e.g., G175m), arginine (e.g., G175R), serine (e.g., G175S), valine (e.g., G175V). In some cases, the proline at amino acid residue 216 of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11 or SEQ ID NO: 12 can be substituted with an amino acid residue such as isoleucine (e.g., P216I). The modified LGIC subunit having selective binding to an exogenous LGIC ligand can include any suitable IPD (e.g., GlyR IPD or GABA. A-ρ IPD). In some aspects, the modified LGIC subunit may include the GlyR IPD shown in SEQ ID NO:5, and the amino acid modification may be a substitution at amino acid residue 298 of the α7-GlyR chimeric receptor (e.g., SEQ ID NO:7). In some cases, the alanine at amino acid residue 298 of SEQ ID NO:7 may be substituted with an amino acid residue such as glycine (e.g., A298G). In some aspects, the modified LGIC subunit may include the GABA shown in SEQ ID NO:9. A-ρ IPD, and the amino acid modification can be α7-GABA A-ρ Substitutions at amino acid residue 298 of a chimeric receptor (eg, SEQ ID NO: 10). In some cases, the tryptophan at amino acid residue 298 of SEQ ID NO: 10 can be substituted with an amino acid residue such as alanine (eg, W298A).

[0333] In some cases, the modified LGIC subunits described herein may include more than one (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more) amino acid modifications. For example, the modified LGIC subunits described herein may have at least 75% sequence identity to SEQ ID NO: 7 and may include a Q79G substitution and an A298G substitution. Other examples of modifications that may confer selective binding of exogenous LGIC ligands to the modified LGIC include modifications described elsewhere (see, e.g., US 8,435,762).

[0334] A modified LGIC subunit that selectively binds (e.g., has enhanced binding or increased potency) to an exogenous LGIC ligand relative to an endogenous (e.g., canonical) LGIC ligand can also be described as having enhanced potency for the exogenous ligand. In some cases, a modified LGIC subunit that selectively binds to an exogenous LGIC ligand as described herein can have at least a 4-fold (e.g., at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, at least 15-fold, at least 16-fold, at least 17-fold, at least 18-fold, at least 19-fold, or at least 20-fold) enhanced potency for the exogenous ligand. In some cases, the modified LGIC subunits described herein that selectively bind to an exogenous LGIC ligand can have an enhanced potency of about 4-fold to about 200-fold (e.g., about 4-fold to about 200-fold, about 5-fold to about 180-fold, about 6-fold to about 175-fold, about 7-fold to about 150-fold, about 8-fold to about 125-fold, about 9-fold to about 100-fold, about 10-fold to about 90-fold, about 11-fold to about 75-fold, about 12-fold to about 65-fold, about 13-fold to about 50-fold, about 14-fold to about 40-fold, or about 15-fold to about 30-fold) for the exogenous ligand. For example, the modified LGIC subunits described herein that selectively bind to an exogenous LGIC ligand can have an enhanced potency of about 10-fold to about 100-fold for the exogenous ligand. For example, the modified LGIC subunits described herein that selectively bind to an exogenous LGIC ligand can have an enhanced potency of about 10-fold to about 20-fold for the exogenous ligand.

[0335] In some aspects, the modified LGIC subunit described herein may include at least one modified amino acid that imparts reduced (e.g., minimized or eliminated) binding to the modified LGIC relative to the unmodified LGIC subunit. The binding to the modified LGIC subunit with the same modification may be selective relative to the binding to the unmodified LGIC subunit. The unmodified LGIC subunit may be a LGIC subunit lacking a modification that imparts reduced binding to the modified LGIC relative to the unmodified LGIC subunit, or the unmodified LGIC may be an endogenous LGIC subunit. The modification that imparts reduced binding to the modified LGIC relative to the unmodified LGIC subunit may be a charge reversal modification. The modified LGIC subunit with reduced binding relative to the unmodified LGIC subunit may include any suitable LBD (e.g., α7 LBD). In some aspects, the modified LGIC subunit may include the α7 LBD shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11, or SEQ ID NO: 12, and the amino acid modification may be a substitution at amino acid residues 27 and / or 41. For example, the arginine at amino acid residue 27 of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11, or SEQ ID NO: 12 may be substituted with aspartic acid (e.g., R27D). For example, the glutamic acid at amino acid residue 41 of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11, or SEQ ID NO: 12 may be substituted with arginine (e.g., E41R). In some cases, the modified LGIC subunit described herein may include an α7 LBD having an R27D substitution and E41R.

[0336] In some aspects, the modified LGIC subunit described herein may include at least one modified amino acid that confers reduced (e.g., minimized or eliminated) binding of an endogenous LGIC ligand to the modified LGIC. The endogenous LGIC ligand may be ACh. The modified LGIC subunit with reduced endogenous LGIC ligand binding may include any suitable IPD (e.g., GlyR LBD). For example, the modified LGIC subunit may include the α7 LBD shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11, or SEQ ID NO: 12, and the amino acid modification may be a substitution at amino acid residues 115, 131, 139, 210, 217, and / or 219. In some cases, the tyrosine at amino acid residue 115 of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11, or SEQ ID NO: 12 may be substituted with phenylalanine (e.g., Y115F). In some cases, the leucine at amino acid residue 131 of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11 or SEQ ID NO: 12 can be substituted with an amino acid residue such as alanine (e.g., L131A), glycine (e.g., L131G), methionine (e.g., L131M), asparagine (e.g., L131N), glutamine (e.g., L131Q), valine (e.g., L131V) or phenylalanine (e.g., L131F). In some cases, the glutamine at amino acid residue 139 of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11 or SEQ ID NO: 12 can be substituted with glycine (e.g., Q139G) or leucine (e.g., Q139L). In some cases, the tyrosine at amino acid residue 210 of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11 or SEQ ID NO: 12 can be substituted with phenylalanine (e.g., Y210F). In some cases, the tyrosine at amino acid residue 217 of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11 or SEQ ID NO: 12 can be substituted with phenylalanine (e.g., Y217F). In some cases, the aspartic acid at amino acid residue 219 of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11 or SEQ ID NO: 12 can be substituted with alanine (e.g., D219A).

[0337] In some aspects, the modified LGIC subunit described herein may include at least one modified amino acid that imparts increased ionic conductance to the modified LGIC. In some cases, the modified LGIC subunit may include the 5HT3 IPD shown in SEQ ID NO:3, and the amino acid modification may be a substitution at amino acid residues 425, 429, and / or 433. For example, the modified LGIC subunit described herein may include a 5HT3 IPD having a R425Q substitution, a R429D substitution, and a R433A substitution. In some cases, the modified LGIC subunit may include the 5HT3IPD shown in SEQ ID NO:4, and the amino acid modification may be a substitution at amino acid residues 420, 424, and / or 428. For example, the modified LGIC subunit described herein may include a 5HT3 IPD having a R420Q substitution, a R424D substitution, and a R428A substitution.

[0338] In some cases, a modified LGIC described herein can include at least one chimeric α7-5HT3 LGIC subunit (SEQ ID NO:6) having a human α7 nAChR LBD (SEQ ID NO:1) having a Q79G amino acid substitution and a Y115F amino acid substitution, and a murine 5HT3 IPD (SEQ ID NO:3).

[0339] In some cases, a modified LGIC described herein can include at least one chimeric α7-5HT3 LGIC subunit (SEQ ID NO:6) having a human α7 nAChR LBD (SEQ ID NO: 1) having a Q79G amino acid substitution and a Q139G amino acid substitution, and a murine 5HT3 IPD (SEQ ID NO:3).

[0340] In some cases, a modified LGIC described herein can include at least one chimeric α7-GlyR LGIC subunit (SEQ ID NO:7) having a human α7nAChR LBD (SEQ ID NO:1) having a Q79G amino acid substitution and a Y115F amino acid substitution, and a human GlyR IPD (SEQ ID NO:5) having an A298G amino acid substitution.

[0341] In some cases, a modified LGIC described herein can include at least one chimeric α7-GlyR LGIC subunit (SEQ ID NO:7) having a human α7nAChR LBD (SEQ ID NO:2) having a Q79G amino acid substitution and a Q139G amino acid substitution, and a human GlyR IPD (SEQ ID NO:5) having an A298G amino acid substitution.

[0342] In some cases, a modified LGIC described herein can include at least one chimeric α7-GlyR LGIC subunit (SEQ ID NO:7) having a human α7nAChR LBD (SEQ ID NO:2) having an R27D amino acid substitution, an E41R amino acid substitution, a Q79G amino acid substitution, and a Y115F amino acid substitution, and a human GlyR IPD (SEQ ID NO:5) having an A298G amino acid substitution.

[0343] In some cases, a modified LGIC described herein can include at least one chimeric α7-GlyR LGIC subunit (SEQ ID NO:7) having a human α7nAChR LBD (SEQ ID NO:2) containing a substitution at amino acid residue 131 (e.g., L131G, L131A, L131M, or L131N), and a human GlyR IPD (SEQ ID NO:5).

[0344] In some cases, a modified LGIC described herein can include at least one chimeric α7-GlyR LGIC subunit (SEQ ID NO:7) having a human α7nAChR LBD (SEQ ID NO:2) containing substitutions at amino acid residues 131 (e.g., L131G, L131A, L131M, or L131N) and Y115 (e.g., Y115F), and a human GlyR IPD (SEQ ID NO:5).

[0345] In some cases, a modified LGIC described herein can include at least one chimeric α7-GlyR LGIC subunit (SEQ ID NO:7) having a human α7nAChR LBD (SEQ ID NO:2) containing substitutions at amino acid residues 131 (e.g., L131G, L131A, L131M, or L131N) and 139 (e.g., Q139L), and a human GlyR IPD (SEQ ID NO:5).

[0346] In some cases, a modified LGIC described herein can include at least one chimeric α7-GlyR LGIC subunit (SEQ ID NO:7) having a human α7nAChR LBD (SEQ ID NO:2) containing substitutions at amino acid residues 131 (e.g., L131G, L131A, L131M, or L131N) and 217 (e.g., Y217F), and a human GlyR IPD (SEQ ID NO:5).

[0347] In some cases, a modified LGIC described herein can include at least one chimeric α7-GlyR LGIC subunit (SEQ ID NO:7) having a human α7nAChR LBD (SEQ ID NO:2) containing substitutions at amino acid residues 131 (e.g., L131G, L131A, L131M, or L131N), 139 (e.g., Q139L), and 217 (e.g., Y217F), and a human GlyR IPD (SEQ ID NO:5).

[0348] In some cases, a modified LGIC described herein can include at least one chimeric α7-5HT3 LGIC subunit having a human α7nAChRLBD (SEQ ID NO: 2) containing a substitution at amino acid residue 131 (e.g., L131G, L131A, L131M, or L131N), and a human 5HT3IPD (SEQ ID NO: 4).

[0349] In some cases, a modified LGIC described herein can include at least one chimeric α7-GlyR LGIC subunit (SEQ ID NO:7) having a human α7 nAChR LBD (SEQ ID NO:2) containing a substitution at amino acid residue 175 (e.g., G175K), and a human GlyR IPD (SEQ ID NO:5).

[0350] In some cases, a modified LGIC described herein can include at least one chimeric α7-5HT3 LGIC subunit having a human α7nAChR LBD (SEQ ID NO: 2) containing substitutions at amino acid residues 131 (e.g., L131G, L131A, L131M, or L131N) and 139 (e.g., Q139L), and a human 5HT3 IPD (SEQ ID NO: 4) having a R420Q substitution, a R424D substitution, and a R428A substitution.

[0351] In some cases, a modified LGIC described herein can include at least one chimeric α7-5HT3 LGIC subunit having a human α7nAChR LBD (SEQ ID NO: 2) containing substitutions at amino acid residues 131 (e.g., L131G, L131A, L131M, or L131N) and 139 (e.g., Q139L) and 217 (e.g., Y217F), and a human 5HT3 IPD (SEQ ID NO: 4) having a R420Q substitution, a R424D substitution, and a R428A substitution.

[0352] In some cases, a modified LGIC described herein can include at least one chimeric α7-GlyR LGIC subunit (SEQ ID NO:7) having a human α7nAChR LBD (SEQ ID NO:2) containing substitutions at amino acid residues 175 (e.g., G175K) and 115 (e.g., Y115F), and a human GlyR IPD (SEQ ID NO:5).

[0353] In some cases, a modified LGIC described herein can include at least one chimeric α7-GlyR LGIC subunit (SEQ ID NO:7) having a human α7nAChR LBD (SEQ ID NO:2) containing substitutions at amino acid residues 175 (e.g., G175K), 115 (e.g., Y115F), and 79 (e.g., Q79G), and a human GlyR IPD (SEQ ID NO:5).

[0354] In some cases, a modified LGIC described herein can include at least one chimeric α7-GlyR LGIC subunit (SEQ ID NO:7) having a human α7nAChR LBD (SEQ ID NO:2) containing substitutions at amino acid residues 175 (e.g., G175K), 77 (e.g., W77F), and 79 (e.g., Q79G), and a human GlyR IPD (SEQ ID NO:5).

[0355] In some cases, a modified LGIC described herein can include at least one chimeric α7-GlyR LGIC subunit (SEQ ID NO:7) having a human α7 nAChR LBD (SEQ ID NO:2) containing a substitution at amino acid residue 216 (e.g., P216I), and a human GlyR IPD (SEQ ID NO:5).

[0356] In some cases, a modified LGIC described herein can include at least one chimeric α7-GlyR LGIC subunit (SEQ ID NO:7) having a human α7nAChR LBD (SEQ ID NO:2) containing substitutions at amino acid residues 216 (e.g., P216I) and 79 (e.g., Q79G), and a human GlyR IPD (SEQ ID NO:5).

[0357] In some cases, the modified LGIC described herein can include at least one chimeric α7-GlyR LGIC subunit (SEQ ID NO: 10) having a human α7nAChR LBD (SEQ ID NO: 2) containing a substitution at amino acid residue 131 (e.g., L131A, L131G, L131M, L131N, L131Q, L131V, or L131F), and a human GABA c IPD (SEQ ID NO:9).

[0358] In some cases, the modified LGIC described herein may include one or more additional polypeptide sequences. The polypeptide sequence may be a transport sequence (e.g., an export sequence and / or a signal sequence). Examples of export sequences include, but are not limited to, an ER export sequence (e.g., FCYENEV (SEQ ID NO: 16)). Examples of signal sequences include, but are not limited to, a CHRNB4 signal sequence (e.g., MRRAPSLVLFFLVALCGRGNC (SEQ ID NO: 17)). The polypeptide sequence may be a targeting sequence. Examples of targeting sequences include, but are not limited to, a KCNB1 somatic cell targeting sequence (e.g., QSQPILNTKEMAPQSKPPEELEMSSMPSPVAPLPARTEGVIDMRSMSSIDSFISCATDFPEATRF (SEQ ID NO: 18)). One or more additional polypeptide sequences may be included in the modified LGIC in any suitable position. In some cases, the additional polypeptide sequence may be a terminal (e.g., C-terminal or N-terminal) polypeptide sequence. In some cases, the additional polypeptide sequence may be an insertion. In some cases, the additional polypeptide sequence may be a substitution.

[0359] In some cases, the modified LGIC described herein can comprise an export sequence. For example, the modified LGIC can comprise an ER export sequence (e.g., FCYENEV (SEQ ID NO: 16). Fig.16 An exemplary modified LGIC is shown in , which contains an α7nAChR LBD with an L131G substitution, a Q139L substitution, and Y217F (e.g., their respective numbering relative to the residues set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:11, or SEQ ID NO:12) and a GlyR IPD with an ER export sequence inserted between residues 142 and 143 (e.g., relative to the residue numbering set forth in SEQ ID NO:5).

[0360] In some cases, the modified LGIC described herein can include a signal sequence. For example, the modified LGIC can include a CHRNB4 signal sequence (eg, MRRAPSLVLFFLVALCGRGNC (SEQ ID NO: 17). Fig.17 An exemplary modified LGIC is shown in , which contains a CHRNB4 signal sequence with substituted residues 1-22, an L131G substitution, a Q139L substitution, and Y217F (e.g., each of which is numbered relative to the residues set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11, or SEQ ID NO: 12).

[0361] In some cases, a modified LGIC described herein can comprise a targeting sequence. For example, a modified LGIC can comprise a KCNB1 somatic targeting sequence (e.g., QSQPILNTKEMAPQSKPPEELEMSSMPSPVAPLPARTEGVIDMRSMSSIDSFISCATDFPEATRF (SEQ ID NO: 18). Fig.18 An exemplary modified LGIC is shown in , which contains an α7 nAChR LBD with an L131G substitution, a Q139L substitution, and a Y217F substitution (e.g., their respective numbers relative to the residues set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11, or SEQ ID NO: 12) and a GlyR IPD with a KCNB1 somatic targeting sequence inserted between residues 142 and 143 (e.g., relative to the residue numbers set forth in SEQ ID NO: 5). Where the LBD and / or IPD is a homolog, ortholog, or paralog of a sequence described herein (e.g., SEQ ID NO: 1-5 and / or 9), it is understood that reference to a particular modified amino acid residue can be transferred to the corresponding amino acid in the homolog, ortholog, or paralog. For example, residues 425, 429, and 433 in the murine 5HT3 IPD set forth in SEQ ID NO:3 correspond to residues 420, 424, and 428 in the human 5HT3 IPD set forth in SEQ ID NO:4, and the R425Q, R429D, and R433A substitutions in the murine 5HT3 IPD correspond to the R420Q, R424D, and R428A substitutions in the human 5HT3 IPD.

[0362] Any method can be used to obtain the modified LGIC subunits described herein. In some cases, peptide synthesis methods can be used to prepare the modified LGIC subunits described herein. Examples of peptide synthesis methods include, but are not limited to, liquid phase peptide synthesis and solid phase peptide synthesis. In some cases, protein biosynthesis methods can be used to prepare the modified LGIC subunits described herein. Examples of protein biosynthesis methods include, but are not limited to, transcription and / or translation of nucleic acids encoding phosphorylation mimetic peptides provided herein. Similar modified LGIC subunits (e.g., modified subunits having substantially the same modifications and / or having substantially the same amino acid sequences) will self-assemble through interactions between LBDs to form modified LGICs.

[0363] This document also provides nucleic acids encoding the modified LGIC subunits described herein and constructs for expressing nucleic acids encoding the modified LGIC subunits described herein (e.g., synthetic constructs such as plasmids, non-viral vectors, viral vectors (e.g., adeno-associated virus, herpes simplex virus, or lentiviral vectors)).

[0364] The nucleic acid sequences encoding the modified LGIC subunits described herein can encode any LGIC described herein. In some cases, the nucleic acid sequences provided herein can encode the LBD from any LGIC described herein. In some cases, the nucleic acid sequences provided herein can encode the IPD from any LGIC described herein. In the case where the nucleic acid sequences provided herein encode chimeric LGICs, the chimeric LGICs can include an LBD selected from any suitable LGIC and an IPD selected from any suitable LGIC.

[0365] In some cases, the nucleic acid sequence can encode a LGIC described herein. For example, the nucleic acid sequence can encode a nAChR (eg, α7nAChR). A representative nucleic acid sequence encoding a rat α7nAChR amino acid sequence (including both LBD and IPD) is as follows.

[0366] SEQ ID NO:19

[0367]

[0368] In some cases, the nucleic acid sequence encoding the modified LGIC subunit described herein can encode the LBD from α7nAChR. Examples of nucleic acid sequences encoding α7nAChR LBD include, but are not limited to, the nucleic acid sequence set forth in SEQ ID NO:20, the nucleic acid sequence set forth in SEQ ID NO:21, and the nucleic acid sequence set forth in SEQ ID NO:22. In some cases, the nucleic acid sequence encoding the α7nAChR LBD can have at least 75% sequence identity (e.g., at least 80%, at least 82%, at least 85%, at least 88%, at least 90%, at least 93%, at least 95%, at least 97%, or at least 99% sequence identity) to SEQ ID NO:20, SEQ ID NO:21, or SEQ ID NO:22.

[0369] SEQ ID NO:20

[0370]

[0371] SEQ ID NO:21

[0372]

[0373] SEQ ID NO:22

[0374]

[0375] In some cases, the nucleic acid sequence encoding the modified LGIC subunit described herein can encode an IPD from 5HT3. Examples of nucleic acid sequences encoding 5HT3 IPD include, but are not limited to, the nucleic acid sequence set forth in SEQ ID NO:23 and the nucleic acid sequence set forth in SEQ ID NO:24. In some cases, the nucleic acid sequence encoding 5HT3 IPD can have at least 75% sequence identity (e.g., at least 80%, at least 82%, at least 85%, at least 88%, at least 90%, at least 93%, at least 95%, at least 97%, or at least 99% sequence identity) to SEQ ID NO:23 or SEQ ID NO:24.

[0376] SEQ ID NO:23

[0377]

[0378] SEQ ID NO:24

[0379]

[0380] In some cases, the nucleic acid sequence encoding the modified LGIC subunit described herein can encode an IPD from GlyR. Examples of nucleic acid sequences encoding GlyR IPD include, but are not limited to, the nucleic acid sequence shown in SEQ ID NO:5. In some cases, the GlyR IPD can be a homologue, a straight homologue or a paralogue of the human GlyR IPD shown in SEQ ID NO:5. In some cases, the GlyR IPD can have at least 75% sequence identity (e.g., at least 80%, at least 82%, at least 85%, at least 88%, at least 90%, at least 93%, at least 95%, at least 97% or at least 99% sequence identity) with SEQ ID NO:25.

[0381] SEQ ID NO:25

[0382]

[0383] In some cases, the nucleic acid sequence encoding the modified LGIC subunit described herein can encode a GABA (e.g., GABA A -ρ, also known as GABAC) IPD. Encoding GABA A Examples of nucleic acid sequences of -ρIPD include, but are not limited to, the nucleic acid sequence shown in SEQ ID NO: 26. In some cases, GABA A The -ρIPD can have at least 75% sequence identity to SEQ ID NO:26 (e.g., at least 80%, at least 82%, at least 85%, at least 88%, at least 90%, at least 93%, at least 95%, at least 97%, or at least 99% sequence identity).

[0384] SEQ ID NO:26

[0385]

[0386] When calculating the sequence identity percentage, two sequences are compared, and the same matching number of amino acid residues between the two sequences is determined. The number of identical matches is divided by the length of the comparison region (that is, the number of nucleic acid residues compared), and multiplied by 100 to obtain the percentage sequence identity value. It should be understood that the length of the comparison region can be a part of one or two sequences, up to the full-length size of the shortest sequence. It should also be understood that a single sequence can be compared with more than one other sequence, therefore, different percentage sequence identity values ​​can be provided on each comparison region. The computer program ClustalW and default parameters can be used to compare two or more sequences to determine the sequence identity percentage, which will calculate the best match between the query sequence and one or more subject sequences, and compare them so that identity, similarity and diversity can be determined. See, for example, Chenna et al., 2003, Nucleic Acids Res., 31 (13): 3497-500.

[0387] The nucleic acid sequence encoding the modified LGIC described herein may include at least one modified nucleic acid such that the nucleic acid sequence may encode an LBD having at least one modified amino acid and / or an IPD having at least one modified amino acid. In some cases, the nucleic acid sequence encoding the modified LGIC described herein may include more than one (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more) modified nucleic acids. For example, the nucleic acid sequence may encode a modified LGIC subunit comprising an α7 LBD having at least 75% sequence identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11, or SEQ ID NO: 12, and having amino acid substitutions at amino acid residues 27, 41, 77, 79, 131, 139, 141, 175, 210, 216, 217, and / or 219. Examples of nucleic acid codons at codon numbers 27, 41, 77, 79, 131, 139, 141, 175, 210, 216, 217 and / or 219 that can result in amino acid substitutions at amino acid residues 27, 41, 77, 79, 131, 139, 141, 175, 210, 216, 217 and / or 219 can be shown below.

[0388] Table 12. Codon usage leading to LBD amino acid substitutions

[0389]

[0390] For example, the nucleic acid sequence may encode a modified LGIC subunit comprising a GlyRIPD having at least 75% sequence identity to the sequence shown in SEQ ID NO: 5 and having an amino acid substitution at amino acid residue 298 of α7-GlyRIPD. Examples of nucleic acid codons at codon number 298 that can result in an amino acid substitution at amino acid residue 298 may be as follows.

[0391] Table 13. Codon usage resulting in GlyR IPD amino acid substitutions

[0392] WT amino acid residues Modified amino acid: modified nucleic acid codon A298 G:GGT

[0393] *Numbers are relative to the residue numbers shown in SEQ ID NO:7

[0394] For example, the nucleic acid sequence can encode a modified LGIC subunit comprising a GABACIPD having at least 75% sequence identity to SEQ ID NO: 9 and having an amino acid substitution at amino acid residue 298 of the α7-GABAC chimeric receptor. Examples of nucleic acid codons at codon number 298 that can result in an amino acid substitution at amino acid residue 298 can be as follows.

[0395] Table 14. Codon usage leading to GABAC IPD amino acid substitutions

[0396] WT amino acid residues Modified amino acid: modified nucleic acid codon W298* A:GCG

[0397] *Numbers are relative to the residue numbers shown in SEQ ID NO: 10

[0398] In some cases, the nucleic acid sequence encoding the modified LGIC described herein can encode an α7-5HT3 chimeric receptor as shown in SEQ ID NO: 6 (e.g., comprising human α7nAChR LBD (SEQ ID NO: 1) and mouse 5HT3 IPD (SEQ ID NO: 3) components). Examples of nucleic acid sequences encoding α7-5HT3 chimeric receptors including human α7nAChR LBD and mouse 5HT3 IPD include, but are not limited to, the nucleic acid sequence shown in SEQ ID NO: 27.

[0399] SEQ ID NO:27

[0400]

[0401] In some cases, the nucleic acid sequence encoding the modified LGIC described herein can encode an α7-GlyR chimeric receptor as shown in SEQ ID NO: 7 (e.g., including human α7nAChR LBD (SEQ ID NO: 2) and human GlyR IPD (SEQ ID NO: 5)). Examples of nucleic acid sequences encoding α7-GlyR chimeric receptors including human α7nAChR LBD and human GlyR IPD include, but are not limited to, the nucleic acid sequence shown in SEQ ID NO: 28.

[0402] SEQ ID NO:28

[0403]

[0404] In some cases, the nucleic acid sequence encoding the modified LGIC described herein can encode the α7-GABAC chimeric receptor shown in SEQ ID NO: 10 (e.g., comprising human α7nAChR LBD (SEQ ID NO: 2) and human GABAC IPD (SEQ ID NO: 9)). Examples of nucleic acid sequences encoding chimeric receptors comprising human α7nAChR LBD (SEQ ID NO: 2) and human GABAC IPD (SEQ ID NO: 9) include, but are not limited to, the nucleic acid sequence shown in SEQ ID NO: 29, wherein the chimeric receptor comprises human α7nAChR LBD and human GABAC IPD.

[0405] SEQ ID NO:29

[0406]

[0407] In some cases, the nucleic acid sequence encoding the modified LGIC described herein may include a nucleic acid sequence encoding one or more additional polypeptide sequences (e.g., a trafficking sequence, such as an export sequence and / or a signal sequence, or a targeting sequence). Examples of nucleic acid sequences encoding export sequences include, but are not limited to, nucleic acid sequences encoding ER export sequences (e.g., TTTTGCTATGAAAACGAAGTC; SEQ ID NO: 30). Examples of nucleic acid sequences encoding signal sequences include, but are not limited to, nucleic acid sequences encoding CHRNB4 signal sequences (e.g., ATGAGAAGGGCCCCATCCCTGGTATTGTTTTTTTTGGTAGCTTTGTGCG GGAGGGGGAACTGC; SEQ ID NO: 31). Examples of nucleic acid sequences encoding targeting sequences include, but are not limited to, nucleic acid sequences encoding a KCNB1 somatic targeting sequence (e.g., CAAAGCCAACCTATCCTTAACACTAAAGAGAGCGCCGCTCAATCCAAACCCAAAGAAGAGTTGGAAATGGAGTCTATACCTTCACCTGTTGCACCTCTCCCTACTAGGACCGAAGGCGTGATTGACATGCGCTCTATGTCTAGTATAGATAGCTTTATATCCTGCGCCACAGACTTTCCCGAAGCCACTAGGTTC; SEQ ID NO: 32).

[0408] In some cases, nucleic acids encoding modified LGIC subunits described herein can be connected (e.g., operably connected) to one or more regulatory elements. For example, nucleic acids encoding modified LGIC subunits described herein can be operably connected to any suitable promoter. The promoter can be a natural (i.e., minimal) promoter or a composite promoter. The promoter can be a ubiquitous (i.e., constitutive) promoter or a regulatory promoter (e.g., inducible, tissue-specific, cell type-specific (e.g., neuron-specific, muscle-specific, glial-specific) and neural subtype-specific). Examples of promoters that can be used to drive expression of nucleic acids encoding modified LGIC subunits described herein include, but are not limited to, synaptophysin (SYN), CAMKII, CMV, CAG, enolase, TRPV1, POMC, NPY, AGRP, MCH and Orexin promoters. In some cases, nucleic acids encoding modified LGIC subunits described herein can be operably connected to neuron-specific promoters.

[0409] In the case of a nucleic acid encoding a modified LGIC subunit described herein in a construct, the construct may be any suitable construct. The construct may be a nucleic acid (e.g., DNA, RNA, or a combination thereof) construct. Examples of constructs include, but are not limited to, plasmids, non-viral vectors, viral vectors (e.g., adeno-associated viral vectors, herpes simplex viral vectors, or lentiviral vectors). In some cases, a construct comprising a nucleic acid encoding a modified LGIC subunit described herein may express a modified LGIC subunit. In some cases, the construct may comprise an internal ribosome entry site (IRES; e.g., a bicistronic IRES). In some cases, the construct may comprise a nucleic acid sequence encoding a detectable marker (e.g., a fluorescent polypeptide, such as a green fluorescent polypeptide (GFP; e.g., enhanced GFP (EGFP))). In some cases, the construct may comprise a nucleic acid sequence that provides a selection marker (e.g., an antibiotic resistance marker, such as ampicillin resistance) for the construct. Figures 19A-19B Shown are exemplary plasmid maps and nucleic acid sequences of constructs including nucleic acid sequences encoding the modified LGIC subunits described herein. Figures 20A-20B Another exemplary plasmid map and nucleic acid sequence of a construct comprising a nucleic acid sequence encoding a modified LGIC subunit described herein is shown.

[0410] This document also provides cells (e.g., mammalian cells) having a modified LGIC as described herein. Mammalian cells having a modified LGIC as described herein can be obtained by any suitable method. In some cases, a preassembled modified LGIC can be provided to the cell. In some cases, a nucleic acid encoding a modified LGIC subunit as described herein can be provided to the cell under conditions where the modified LGIC subunit is translated and where multiple (e.g., 3, 4, 5, 6 or more) modified LGIC subunits can be assembled into a modified LGIC as described herein.

[0411] LGIC ligand

[0412] This document also provides LGIC ligands that can bind to and activate the modified LGIC described herein. LGIC ligands can also be referred to as pharmacologically selective effector molecules (PSEMs). LGIC ligands that can bind to and activate the modified LGIC described herein can be exogenous or endogenous. LGIC ligands that can bind to and activate the modified LGIC described herein can be naturally occurring or synthetic. LGIC ligands that can bind to and activate the modified LGIC described herein can be canonical or non-canonical. LGIC ligands that can bind to and activate the modified LGIC described herein can be agonists or antagonists. In some cases, the LGIC ligand is an exogenous LGIC agonist. Examples of LGIC ligands include, but are not limited to, ACh, nicotine, epibatatine, cytisine, RS56812, tropisetron, nortropisetron, PNU-282987, PHA-543613, Compound 0353, Compound 0354, Compound 0436, Compound 0676, Compound 702, Compound 723, Compound 725, granisetron, dihydrovermectin, mequitazine, promazine, varenicline, Compound 765, Compound 770, 3-(1,4-diazabicyclo[3.2.2]non-4-yl)dibenzo[b,d]thiophene 5,5-dioxide, Compound 773, and Compound 774 (see, e.g., Figure 3B , Figure 5C , Fig.11A , Fig. 11B and Fig. 11C ).

[0413] LGIC ligands that can bind to and activate a modified LGIC described herein can have selective binding (e.g., enhanced binding or increased potency) for a modified LGIC described herein (e.g., relative to an unmodified LGIC). In some cases, LGIC ligands that can bind to and activate a modified LGIC described herein do not bind to and activate an endogenous receptor (e.g., an endogenous LGIC). LGIC ligands that selectively bind to and activate a modified LGIC described herein (e.g., a modified LGIC having at least one amino acid modification that confers pharmacological selectivity for the modified LGIC) relative to an unmodified LGIC ligand can also be described as having enhanced potency for the modified LGIC. In some cases, the modified LGIC subunit described herein that selectively binds an exogenous LGIC ligand can have at least 5-fold (e.g., at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 30-fold, at least 35-fold, at least 40-fold, at least 45-fold, at least 50-fold, at least 55-fold, at least 60-fold, at least 65-fold, at least 70-fold, at least 75-fold, at least 80-fold, at least 85-fold, at least 95-fold, at least 100-fold, at least 125-fold, at least 150-fold, at least 200-fold, at least 250-fold, or at least 300-fold) enhanced potency over the modified LGIC. For example, an LGIC ligand that selectively binds to and activates a modified LGIC can have an enhanced potency for the modified LGIC by about 10-fold to about 300-fold (e.g., about 10-fold to about 250-fold, about 10-fold to about 200-fold, about 10-fold to about 150-fold, about 10-fold to about 100-fold, about 25-fold to about 300-fold, about 50-fold to about 300-fold, about 100-fold to about 300-fold, about 200-fold to about 300-fold, about 25-fold to about 250-fold, about 50-fold to about 200-fold, or about 100-fold to about 150-fold). In some cases, a LGIC ligand that binds to and activates a modified LGIC described herein can have a ligand potency of less than 25 nM (e.g., less than 22 nM, less than 20 nM, less than 17 nM, less than 15 nM, less than 13 nM, less than 12 nM, less than 11 nM, less than 10 nM, less than 5 nM, less than 2 nM, or less than 1 nM). For example, a LGIC ligand that binds to and activates a modified LGIC described herein can have a ligand potency of less than 15 nM. In some cases, a LGIC ligand can have an EC50 of less than 25 nM for a modified LGIC subunit described herein (e.g., less than 22 nM, less than 20 nM, less than 17 nM, less than 15 nM, less than 13 nM, less than 12 nM, less than 11 nM, or less than 10 nM). For example, a LGIC ligand (e.g., tropisetron) can have an EC50 of less than 25 nM for a modified LGIC subunit described herein (e.g., α7 Q79G -GlyR A298G) can have an EC50 of about 11 nM. For example, a LGIC ligand (e.g., nortropisetron) can have an EC50 of about 11 nM for a modified LGIC subunit described herein (e.g., α7 Q79G,Y115F -GlyR A298G ) can have an EC50 of about 13 nM. In some cases, the LGIC ligand can have an EC50 of greater than 20 μM (e.g., greater than 22 μM, greater than 25 μM, greater than 35 μM, greater than 50, greater than 65 μM, greater than 80 μM, or greater than 100 μM) for a modified LGIC subunit described herein. For example, a LGIC ligand (e.g., ACh) can have an EC50 of about 13 nM for a modified LGIC subunit described herein (e.g., α7 Q79G,Y115F -GlyR A298G ) can have an EC50 greater than 100 μM.

[0414] In some aspects, the LGIC ligand can be a synthetic ligand capable of binding to and activating the modified LGIC described herein, which can be quinuclidine, tropane, 9-azabicyclo[3.3.1]nonane, or 2-phenyl-7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline.

[0415] LGIC ligands that can target and activate the modified LGIC described herein can have Formula I:

[0416]

[0417] Wherein X1 and X2 can be independently CH, CH2, O, NH or NMe; each n can be independently 0 or 1; Y can be O or S; A can be an aromatic substituent; and R can be H or pyridylmethylene. Examples of aromatic substituents include, but are not limited to, 4-chloro-benzene, 1H-indole, 4-(trifluoromethyl)benzene, 4-chlorobenzene, 2,5-dimethoxybenzene, 4-chloroaniline, aniline, 5-(trifluoromethyl)pyridin-2-yl, 6-(trifluoromethyl)nicotine and 4-chloro-benzene.

[0418] The LGIC ligand that can bind to and activate the modified LGIC described herein can be quinuclidine. Quinuclidine can have the structure of Formula II:

[0419]

[0420] Wherein X3 can be O, NH or CH2; Y can be O or S; A can be an aromatic substituent; and R can be H or pyridylmethylene. Examples of aromatic substituents include, but are not limited to, 1H-indole, 4-(trifluoromethyl)benzene, 4-chlorobenzene, 2,5-dimethoxybenzene, 4-(trifluoromethyl)benzene, 4-chloroaniline, aniline, 5-(trifluoromethyl)pyridin-2-yl, 6-(trifluoromethyl)nicotine, 3-chloro-4-fluorobenzene, 4-chloro-benzene, and 1H-indole. Examples of quinoline include, but are not limited to, compounds PNU-282987, PHA-543613, 0456, 0434, 0436, 0354, 0353, 0295, 0296, and 0676 (see, e.g. Figure 5C , Table 3 and Table 6).

[0421] The LGIC ligand that can bind to and activate the modified LGIC described herein can be tropane. Tropane can have the structure of Formula III:

[0422]

[0423] Wherein X2 can be NH or NMe; X3 can be O, NH or CH2; Y can be O or S; and A can be an aromatic substituent. Examples of aromatic substituents include, but are not limited to, 1H-indole, 7-methoxy-1H-indole, 7-methyl-1H-indole, 5-chloro-1H-indole, and 1H-indazole. Examples of tropanes include, but are not limited to, tropisetron, pseudo-tropisetron, nortropisetron, compound 737, and compound 745 (see, e.g., Figure 5C , Table 3 and Table 6).

[0424] The LGIC ligand that can bind to and activate the modified LGIC described herein can be 9-azabicyclo[3.3.1]nonane. 9-azabicyclo[3.3.1]nonane can have a structure of Formula IV:

[0425]

[0426] Wherein R1=H, aromatic substituent, group containing methyl, group containing ethyl or other aliphatic group, group containing alkoxy (for example, group containing methoxy, group containing ethoxy, group containing propoxy and group containing isopropoxy); or group containing amino; and R2=H, aliphatic substituent (for example, methyl) or aromatic substituent (for example, phenyl). Examples of R1 groups include, but are not limited to, phenyl, 2-toluoyl, 3-pyridyl, 4-pyridyl, imidazole, pyrrole, pyrazole, triazole, isoxazol-3-amine, trifluoromethyl, methoxy, N,N-dimethylamino and N,N-diethylamino. In some cases, R1 and R2 can be connected to form a ring. Examples of 6,7,8,9-tetrahydro-6,10-methano-6H-pyrazino(2,3-h)benzazepines include, but are not limited to, varenicline, compound 0765, compound 0770, compound 0780, compound 0782, compound 0785, compound 0788, compound 0782, compound 0789, compound 0791, compound 0793, compound 0794, compound 0795, compound 0798, compound 0799, compound 0800, compound 0801, compound 0802, compound 0803, compound 0804, compound 0805, compound 0807, compound 0808, compound 0812, compound 0813, compound 815, compound 816, and compound 817 (e.g., see Fig.11A , Fig.14A , Table 3, Table 9, Table 10 and Table 11).

[0427] In some cases, the LGIC ligand can be 2-(pyridin-3-yl)-1,5,6,7,8,9-hexahydro-5,9-methanoimidazo[4',5':4,5]benzo[1,2-d]azepine;

[0428]

[0429] Examples of 2-(pyridin-3-yl)-1,5,6,7,8,9-hexahydro-5,9-methanoimidazo[4′,5′:4,5]benzo[1,2-d]azepines include Compound 0786 (see, eg, Table 10 and Table 11).

[0430] In some cases, the LGIC ligand can be 7,8,9,10-tetrahydro-1H-6,10-methanoazepine[4,5-g]quinoxalin-2(6H)-one and can have the structure shown in Formula VI:

[0431]

[0432] wherein R1=H or an aliphatic substituent (e.g., methyl); wherein R2=H, an aliphatic substituent (e.g., methyl) or an aromatic substituent; and wherein R3=O or S. Examples of 7,8,9,10-tetrahydro-1H-6,10-methanoazepine[4,5-g]quinoxaline-2(6H)-one include, but are not limited to, Compound 0783, Compound 0784, Compound 0790, or Compound 0792 (see, e.g., Fig. 11B , Table 10 and Table 11). For example, LGIC can be 7,8,9,10-tetrahydro-1H-6,10-methanoazepine [4,5-g] quinoxaline-2 (6H) -one having the following structure:

[0433]

[0434] In some cases, the LGIC ligand can be 1,4-diazabicyclo[3.2.2]nonane, and can have the structure shown in Formula VII:

[0435]

[0436] Wherein R = H, F, NO2. Examples of 1,4-diazabicyclo[3.2.2]nonane include, but are not limited to, 3-(1,4-diazabicyclo[3.2.2]non-4-yl)dibenzo[b,d]thiophene 5,5-dioxide, Compound 0773 and Compound 0774 (see, e.g. Fig. 11C , Table 6 and Table 9).

[0437] How to use

[0438] This document also provides methods of using the modified LGICs and LGIC ligands described herein, which can bind to and activate the modified LGICs as described herein.LGIC ligands that can bind to and activate the modified LGICs can be used to activate the modified LGICs with temporal and / or spatial control based on the delivery of the ligand.

[0439] In some aspects, the modified LGICs described herein and LGIC ligands that can bind to and activate the modified LGICs as described herein can be used to identify ligands that selectively bind to the modified LGICs described herein. For example, such screening methods can include providing one or more candidate ligands to the modified LGICs described herein, and detecting binding between the candidate ligands and the modified LGICs.

[0440] Any suitable method can be used to detect the binding between the candidate ligand and the modified LGIC, and any suitable method can be used to detect the activity of the modified LGIC. For example, the ability of the ligand to bind and activate the modified LGIC can be measured by an assay including, but not limited to, a membrane potential (MP) assay (e.g., a fluorescent MP assay), a radioactive binding assay, and / or voltage clamp measurements of peak current and sustained current.

[0441] In some aspects, the modified LGICs described herein and LGIC ligands that can bind to and activate the modified LGICs as described herein can be used to treat mammals with channelopathies (e.g., neural channelopathies or muscle channelopathies). For example, a mammal with a channelopathic disorder can be treated by administering a modified LGIC as described herein, followed by administering an LGIC ligand that can bind to and activate the modified LGIC. For example, a mammal with a channelopathic disorder can be treated by administering a modified LGIC as described herein (e.g., comprising at least one chimeric α7-GlyR LGIC subunit (SEQ ID NO: 6), having a human α7nAChRLBD (SEQ ID NO: 2) containing an R27D amino acid substitution, an E41R amino acid substitution, a Q79G amino acid substitution, and a Y115F amino acid substitution, and a human GlyR IPD (SEQ ID NO: 5) having an A298G amino acid substitution), followed by administering tropisetron. For example, a mammal having a channelopathy can be treated by administering a modified LGIC described herein, comprising a modified human α7nAChR LBD (e.g., SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11, or SEQ ID NO: 12) having an L131 amino acid substitution (e.g., L131G, L131A, L131M, or L131N) and optionally a Q79S amino acid substitution, a Q139L amino acid substitution, and / or a Y217F amino acid substitution, followed by administration of varenicline, tropisetron, and / or compound 765.

[0442] Any type of mammal can be treated using the modified LGICs described herein and LGIC ligands that can bind to and activate the modified LGICs as described herein. For example, humans and other primates such as monkeys can be treated using the modified LGICs described herein and LGIC ligands that can bind to and activate the modified LGICs as described herein. In some cases, dogs, cats, horses, cattle, pigs, sheep, rabbits, mice, and rats can be treated using the modified LGICs described herein and LGIC ligands that can bind to and activate the modified LGICs as described herein.

[0443] Any suitable method may be used to identify mammals having a channelopathy and / or mammals at risk of developing a channelopathy. For example, genetic testing may be used to identify mammals having a channelopathy and / or mammals at risk of developing a channelopathy.

[0444] Once a mammal has been identified as having a channelopathy and / or at risk of developing a channelopathy, the mammal can be administered or instructed to self-administer a modified LGIC as described herein, and then administered or instructed to self-administer a LGIC ligand that can bind to and activate a modified LGIC as described herein. The modified LGIC as described herein and the LGIC ligand that can bind to and activate a modified LGIC as described herein can be administered together or can be administered separately.

[0445] When treating a mammal suffering from a channelopathy and / or a mammal at risk of developing a channelopathy using materials and methods as described herein, the channelopathy can be any channelopathy. As used herein, a channelopathy can be any disease or condition caused by abnormal ion channel function and / or abnormal ligand function, or any disease or condition that can be alleviated by regulating ion channel function and / or altered cell ion flux (e.g., calcium ion flux). Channelopathy can be congenital or acquired. Examples of channelopathies include, but are not limited to, Bartter syndrome, Brugada syndrome, catecholamine-dependent ventricular tachycardia (CPVT), congenital hyperinsulinemia, cystic fibrosis, Dravet syndrome, paroxysmal ataxia, erythromelalgia, generalized epilepsy (e.g., with febrile seizures), familial hemiplegic migraine, fibromyalgia, hyperkalemic periodic paralysis, hypokalemic periodic paralysis, Lambert myasthenic syndrome, long QT syndrome (e.g., Romano-Ward syndrome), short QT syndrome, malignant hyperthermia, mucolipidosis type IV, myasthenia gravis, myotonia congenita, neuromyelitis optica, neuromyotonia, nonsyndromic deafness, paramyotonia congenita, retinitis pigmentosa, timothy syndrome, tinnitus, seizures, trigeminal neuralgia, and multiple sclerosis. Alternatively, or additionally, the materials and methods described herein may be used in other applications including, but not limited to, pain treatment, cancer cell therapy, appetite control, spasticity treatment, dystonia treatment, tremor treatment, and movement disorder treatment.

[0446] In some cases, the modified LGICs described herein and the LGIC ligands that can bind to and activate the modified LGICs as described herein can be used to regulate the activity of cells. The cell activity regulated using the modified LGICs described herein and the LGIC ligands that can bind to and activate the modified LGICs as described herein can be any cell activity. Examples of cell activities include, but are not limited to, active transport (e.g., ion transport), passive transport, excitation, inhibition, ion flux (e.g., calcium ion flux), and exocytosis. Cell activity can be increased or decreased. For example, the modified LGICs described herein and the LGIC ligands that can bind to and activate the modified LGICs as described herein can be used to regulate (e.g., increase) ion transport across the cell membrane. For example, the modified LGICs described herein and the LGIC ligands that can bind to and activate the modified LGICs as described herein can be used to regulate (e.g., increase) the excitability of cells.

[0447] The modified LGICs described herein and LGIC ligands that can bind to and activate the modified LGICs described herein can be used to regulate the activity of any type of cell in a mammal. The cell can be a neuron, a glial cell, a muscle cell, an immune cell (e.g., a neutrophil, an eosinophil, a basophil, a lymphocyte, and a monocyte), an endocrine cell, or a stem cell (e.g., an embryonic stem cell). In some cases, the cell can be an excitable cell. The cell can be in vivo or in vitro.

[0448] The modified LGIC described herein can be administered by any suitable method. The modified LGIC can be administered as a modified LGIC subunit or as a preassembled modified LGIC. The modified LGIC can be administered as a nucleic acid encoding the modified LGIC. The modified LGIC can be administered as a nucleic acid encoding the modified LGIC subunit described herein. For example, the nucleic acid can be delivered as a naked nucleic acid or using any suitable vector (e.g., a recombinant vector). The vector can be a DNA-based vector, an RNA-based vector, or a combination thereof. The vector can express the nucleic acid in a dividing cell or a non-dividing cell. Examples of recombinant vectors include, but are not limited to, plasmids, viral vectors (e.g., retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and herpes simplex viral vectors), cosmids, and artificial chromosomes (e.g., yeast artificial chromosomes or bacterial artificial chromosomes). In some cases, the nucleic acid encoding the modified LGIC subunit described herein can be expressed by an adeno-associated viral vector.

[0449] The modified LGIC described herein can be detected by any appropriate method (e.g., to confirm its presence in a cell). In some cases, a reagent that selectively binds to the modified LGIC can be used to detect the modified LGIC. Examples of reagents that can be used to bind to the modified LGIC described herein include, but are not limited to, antibodies, proteins (e.g., bungarus toxins), and small molecule ligands (e.g., PET ligands). Reagents that selectively bind to the modified LGIC can include detectable markers (e.g., fluorescent markers, radioactive markers, positron emission markers, and enzyme markers). Methods for detecting LGIC expression in cells can include fluorescence imaging, autoradiography, functional MRI, PET, and SPECT.

[0450] The modified LGICs described herein and LGIC ligands that can bind to and activate a modified LGIC as described herein can be administered to a mammal having a channelopathy and / or at risk of developing a channelopathy as a combination therapy with one or more additional agents / therapies for treating the channelopathy. For example, a combination therapy for treating a mammal having a channelopathy as described herein can include administering a modified LGIC as described herein and a LGIC ligand that can bind to and activate a modified LGIC as described herein, and treating with acetazolaminde, dichlorphenamide, mexilitine, glucose, calcium gluconate, L-DOPA, muscle stimulation, spinal stimulation, brain stimulation, and / or nerve stimulation.

[0451] In embodiments where the modified LGIC described herein and the LGIC ligands that can bind and activate the modified LGIC as described herein are combined with other agents / therapies for treating channel diseases, one or more additional agents can be administered simultaneously or independently. For example, the modified LGIC described herein and the LGIC ligands that can bind and activate the modified LGIC as described herein are first administered, and then one or more additional agents are administered, or vice versa. In embodiments where the modified LGIC described herein and the LGIC ligands that can bind and activate the modified LGIC as described herein are used in combination with one or more additional therapies for treating channel diseases, one or more additional therapies can be administered simultaneously or independently while administering the modified LGIC described herein and the LGIC ligands that can bind and activate the modified LGIC as described herein. For example, the modified LGIC described herein and the LGIC ligands that can bind and activate the modified LGIC as described herein can be administered before, during, or after performing one or more additional therapies.

[0452] In some cases, the modified LGICs described herein and / or LGIC ligands that can bind to and activate the modified LGICs as described herein can be formulated into pharmaceutically acceptable compositions for administration to mammals suffering from channel diseases or at risk of developing channel diseases. For example, a therapeutically effective amount of a modified LGIC as described herein (e.g., a nucleic acid encoding a modified LGIC as described herein) and / or a LGIC ligand that can bind to and activate the modified LGICs as described herein can be formulated with one or more pharmaceutically acceptable carriers (additives) and / or diluents. Pharmaceutical compositions can be formulated for administration in solid or liquid form, including but not limited to sterile solutions, suspensions, sustained release formulations, tablets, capsules, pills, powders, and granules.

[0453] Pharmaceutically acceptable carriers, fillers and vehicles that can be used in the pharmaceutical compositions described herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, polyethylene glycol and lanolin.

[0454] Pharmaceutical compositions containing modified LGICs as described herein and / or LGIC ligands that can bind and activate modified LGICs as described herein can be designed for oral, parenteral (including subcutaneous, intracranial, intraarterial, intramuscular, intravenous, intracoronary, intradermal, or topical), or inhalation administration. When administered orally, pharmaceutical compositions containing a therapeutically effective amount of modified LGICs as described herein (e.g., nucleic acids encoding modified LGICs as described herein) and / or LGIC ligands that can bind and activate modified LGICs as described herein can be in the form of pills, tablets, or capsules. Compositions suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that make the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions, which can include suspending agents and thickening agents. Compositions for inhalation can be delivered using, for example, an inhaler, a nebulizer, and / or a dry powder inhaler. The formulations can be presented in unit-dose or multi-dose containers, such as sealed ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition, requiring only the addition of a sterile liquid carrier, such as water for injection, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules and tablets.

[0455] A pharmaceutically acceptable composition comprising a therapeutically effective amount of a modified LGIC as described herein (e.g., a nucleic acid encoding a modified LGIC as described herein) and / or a LGIC ligand that can bind to and activate a modified LGIC as described herein can be administered topically or systemically. In some cases, a composition comprising a therapeutically effective amount of a modified LGIC as described herein (e.g., a nucleic acid encoding a modified LGIC as described herein) and / or a LGIC ligand that can bind to and activate a modified LGIC as described herein can be administered systemically by intravenous or oral administration to a mammal (e.g., a human) or by inhalation by a mammal (e.g., a human). In some cases, a composition comprising a therapeutically effective amount of a modified LGIC as described herein (e.g., a nucleic acid encoding a modified LGIC as described herein) and / or a LGIC ligand that can bind to and activate a modified LGIC as described herein can be administered topically to a target tissue of a mammal (e.g., a human) by transdermal, subcutaneous, intramuscular, intracranial, or open surgical administration (e.g., injection).

[0456] The effective dosage may vary depending on the severity of the channelopathy, the route of administration, the age and general health of the subject, the use of excipients, the possibility of co-administration with other treatments (eg, use of other agents), and the judgment of the treating physician.

[0457] The frequency of administration can be any frequency that improves the symptoms of channel diseases without producing significant toxicity to mammals. For example, the frequency of administration can be from about once a week to about three times a day, from about twice a month to about six times a day, or from about twice a week to about once a day. The frequency of administration can remain constant or can change during the treatment duration. The process of treating with a composition containing a therapeutically effective amount of a modified LGIC as described herein (e.g., a nucleic acid encoding a modified LGIC as described herein) and / or a composition that can bind and activate a LGIC ligand of a modified LGIC as described herein can include a rest period. For example, a composition containing a therapeutically effective amount of a modified LGIC as described herein (e.g., a nucleic acid encoding a modified LGIC as described herein) and / or a composition that can bind and activate a LGIC ligand of a modified LGIC as described herein can be administered daily over a two-week period, followed by a two-week rest period, and such a regimen can be repeated multiple times. As with the effective amount, various factors can affect the actual frequency of administration for a particular application. For example, the effective amount, duration of treatment, use of multiple therapeutic agents, route of administration, and severity of channel diseases can require an increase or decrease in the frequency of administration.

[0458] The effective duration of administration of a composition containing a therapeutically effective amount of a modified LGIC as described herein (e.g., a nucleic acid encoding a modified LGIC as described herein) and / or a LGIC ligand that can bind to and activate a modified LGIC as described herein can be any duration that can improve channelopathy symptoms without causing significant toxicity to a mammal. For example, the effective duration can vary from a few days to a few weeks, a few months, or a few years. In some cases, the effective duration for treating a channelopathy can range from a duration of about one month to about 10 years. Various factors can affect the actual effective duration for a particular treatment. For example, the effective duration can vary with the frequency of administration, the effective amount, the use of a variety of therapeutic agents, the route of administration, and the severity of the channelopathy being treated.

[0459] In some cases, the course of treatment and the mammal being treated for a channelopathy may be monitored for symptoms.Symptoms of a channelopathy may be monitored using any suitable method.

[0460] The present invention will be further described in the following examples, which do not limit the scope of the invention described in the claims. Example

[0461] Example 1: Potency-enhancing ligand binding domain mutations

[0462] A panel of 41 α7-5HT3 chimeric channels with mutant LBDs were screened against a panel of 51 clinically used drugs that are chemically similar to nicotinic receptor agonists. Figures 1A-1E The screening revealed that Gln in the α7nAChR LBD 79 , which enhances the potency of the known nAChR agonist tropisetron ( Figure 2 These mutations (Q79A, Q79G, Q79S) reduce the size of the amino acid side chains. Some mutant ion channel-ligand combinations gave up to 12-fold improvement in potency (Table 1, Figure 3A-3B ). The canonical α7nAChR agonists, Ach, nicotine, epibatidine, and the anti-smoking drug varenicline were not significantly affected by the Q79A, Q79G, or Q79S mutations. However, a subset of α7nAChR agonists showed enhanced potency in the presence of some mutations. Cytisine, RS56812, tropisetron, nortropisetron, and PNU-282987 showed significantly improved potency against α7Q79G-5HT3. In addition, nortropisetron and PNU-282987 showed significant potency against α7Q79G-5HT3, respectively. Q79A -5HT3 and α7 Q79S-5HT3 significantly enhanced potency. In general, agonists based on quinine or tropane pharmacophores with linked aromatic structures that interact with the complementary binding surface of the ligand binding domain show improved potency when Gln79 is substituted with smaller amino acid residues Ala, Gly or Ser. For most agonists, α7 Q79G -5HT3 is the most preferred mutant chimeric ion channel.

[0463] Table 1. Potency of nAChR agonists on chimeric cation channels mutated at Gln79 in HEK cells. Mean EC50 with SEM in brackets (μM).

[0464] Agonists α7-5HT3 <![CDATA[α7 Q79A -5HT3]]> <![CDATA[α7 Q79G -5HT3]]> <![CDATA[α7 Q79S -5HT3]]> Acetylcholine 7.0(0.8) 9.2(1.8) 6.7(0.6) 6.2(1.4) Nico 3.9(0.4) 4.1(1.3) 3.1(0.5) 2.1(0.4) Epibatidine 0.053(0.006) 0.067(0.022) 0.050(0.008) 0.044(0.006) Varenicline 0.92(0.16) 0.76(0.21) 0.91(0.12) 0.47(0.07) Cytisine 8.2(0.3) 4.0(0.9) 1.7(0.2) 4.4(1.0) RS56812 10(1.8) 6.8(1.9) 1.4(0.2) 5.7(0.8) Tropisetron 0.24(0.03) 0.08(0.02) 0.035(0.002) 0.11(0.02) Tropisetron 0.061(0.021) 0.010(0.002) 0.006(0.001) 0.019(0.007) PNU-282987 0.22(0.03) 0.037(0.009) 0.018(0.003) 0.023(0.004)

[0465] Use of these mutant LBDs generated α7-GlyR chimeric channels that had up to 6-fold enhanced potency for most of these ligands ( Figure 4A ). As with mutations in α7-5HT3, these mutations at Gln79 did not significantly affect the potency of ACh, nicotine, epibatidine, varenicline, or cytisine. However, tropisetron, nortropisetron, and RS56812 showed significant effects on α7 Q79G Similar to the LBD mutation of α7-5HT3, nortropisetron has a significant effect on α7 Q79A -GlyR has significantly enhanced potency, and PNU-282987 shows Q79S -GlyR. For most agonists, α7 Q79G -GlyR is the most preferred mutant chimeric ion channel.

[0466] Another relationship observed in the small molecule screen is that mutations at Trp77 W77F -5HT3 (EC50: 1.2 μM), α7 W77Y -5HT3 (EC50: 1.1 μM) and α7 W77F -GlyR (EC50: 0.66 μM) receptors conferring agonist activity to the drug granisetron. Granisetron is a 5HT3 receptor antagonist that does not activate α7-5HT3 or α7-GlyR.

[0467] These results show that mutation of Q79 (to A, G or S) in the α7 nAChR LBD enhances the binding of known LGIC ligands to the modified LGIC.

[0468] Example 2: Potency-enhancing ion pore domain mutations

[0469] The enhanced potency of the allosteric agonist dihydrotestosterone was tested on α7-GlyR channels with IPD mutations previously established in full-length glycine receptor channels (T258S and A288G, GlyR numbering; equivalent to T268S and A298G in α68-GlyR numbering). T268S The channels have a substantial ligand-free open probability, which makes them unsuitable for ligand-controlled cellular manipulation. A298G Mutations in , which effectively enhance the potency of dihydrochloride at the full-length glycine receptor, result in modest changes in the probability of opening in the absence of ligand; therefore, activity against a panel of known agonists was examined for this channel. For the canonical agonists ACh, nicotine, and epibatidine, as well as for varenicline and tropisetron, agonist potency was not significantly different at α7-GlyR. A298G A subset of α7 nAChR agonists did show up to a modest 4-fold increase in potency: RS56812, cytisine, PNU-282987, and nortropisetron were significantly more potent. Thus, the effect of the IPDA298G mutation improves ligand potency but is ligand structure dependent and less effective than mutations in the LBD.

[0470] The Q79G mutation in the LBD and the A298G IPD mutation in α7-GlyR were examined (Table 2). Q79G -GlyR A298G The results were synergistic, with up to 18-fold potency enhancement for α7 nAChR agonists relative to α7-GlyR. The enhancement for this double mutant channel was greater than that from the individual mutations for the agonists RS56812, tropisetron, nortropisetron, and PNU-282987. Further emphasizing the unexpected structural sensitivity of this mutation combination, multiple agonists such as ACh, nicotine, epibatidine, varenicline, and cytisine were found to be highly potent at both α7-GlyR and α7. Q79G -GlyR A298G Thus, the combination of the LBD mutation Q79G and the IPD mutation A298G produces a synergistic effect, with the potency of some, but not all, nicotinic agonists greatly increased by about 10-20 fold.

[0471] Table 2. Potency of nAChR agonists on mutant chimeric chloride channels. Mean EC50 and SEM in parentheses (μM) of agonist activity in HEK cells expressing chimeric channels.

[0472]

[0473] These results show that mutation of Q79 (to A, G or S) in the α7nAChR LBD and / or mutation of A298 (to G) in the GlyR IPD further enhances the selective binding of known LGIC ligands to the modified LGIC.

[0474] Example 3: Molecules exhibiting enhanced efficacy

[0475] Based on α7 Q79G -GlyR A298G Based on the structure activity relationship of known agonists that showed enhanced potency in the absence of quinuclidine, tropane, or 9-azabicyclo[3.3.1]nonane pharmacophores with one or more aromatic side chain substituents, various synthetic molecules were tested. In addition, the known α7 nAChR agonist PHA-543613 (Walker et al. 2006, Wishka et al. 2006) was also tested and showed enhanced potency for α7. Q79G -GlyR A298G These molecules typically showed enhanced potency 10- to 100-fold (Table 3), indicating that for these pharmacophores, a range of structural features are associated with targeting α7 Q79G -GlyR A298G The improved effectiveness is compatible.

[0476] These results show that the modified LGIC can be activated by quinuclidine-containing and tropane-containing synthetic LGIC ligands.

[0477]

[0478] Example 4: Mutations that reduce acetylcholine responsiveness

[0479] Compared to other nAChR isoforms, α7 nAChRs have relatively low sensitivity to ACh, and potency-enhancing mutations for tropane and quinuclidine ligands do not substantially alter the potency of acetylcholine at these channels. Therefore, chimeric channels were further modified to reduce the acetylcholine responsiveness of these channels. In some cases, acetylcholine responsiveness was substantially reduced to over 100 μM with the additional LBD mutations Y115F and Q139G, which only modestly reduced the potency of certain agonists to α7. Q79G,Y115F -5HT3, α7 Q79G,Q139G -5HT3, α7 Q79G,Q139G -GlyR A298 、α7 Q79G,Y115F -GlyR A298G For example, α7 Q79G,Y115F -GlyR A298GThe EC50 for nortropisetron was 13 nM and the EC50 for ACh was >100 μM (Table 4).

[0480] Table 4. Potency of nAChR agonists on mutant chimeric chloride channels with low acetylcholine responsiveness.

[0481] Mean EC50 and SEM in brackets (μM) for activity in HEK cells expressing the chimeric channels.

[0482]

[0483] These results show that the Y115F and / or Q139G mutations in the α7nAChR LBD reduce the binding of the endogenous LGIC ligand Ach to the modified LGIC.

[0484] Example 5: Mutations that reduce binding to endogenous receptor subunits

[0485] The assembly of α7nAChR is based on the binding of five homopolymer subunits through the interaction between LBD (Celie et al 2004 Neuron 41: 907-14). In order to minimize the undesirable binding and / or undesirable binding of the chimeric channel with endogenous α7nAChR subunits, potential intersubunit salt bridges were identified by examining the crystal structure of acetylcholine binding protein and identifying nearby intersubunit residues with opposite charges, which also had homologous ionic amino acids in the α7nAChR receptor LBD. Charge reversal mutations (converting the acidic members of potential salt bridges to basic residues and converting their basic partners to acidic residues) were designed to destroy the intersubunit interactions with unmodified subunits, but retain the interactions between subunits with charge reversal mutations ( Fig. 6A ). Chimeric LGIC subunits with charge reversal mutations are able to selectively assemble with each other without interacting with unmodified channels, such as endogenous α7nAChR. Double mutations of R27D, E41R in the α7nAChR LBD produce functional channels ( Figure 6B ). Co-expression of these charge-reversal channels with α7-5HT3 channels with unmodified sequences showed that the charge-reversal subunits did not co-immunoprecipitate with the unmodified channels ( Figure 6C ). Combined with potency enhancing mutations and acetylcholine blocking mutations to give chimeric channel α7 R27D,E41R,Q79G,Y115F -GlyR A298G It was revealed that some agonists retained high potency against their cognate agonists (Table 4, right column).

[0486] These results show that the R27D and E41R mutations in the α7 nAChR LBD reduce the binding of modified LGIC subunits to other modified and / or endogenous LGIC subunits.

[0487] Example 6: LBD mutations that increase ligand potency

[0488] Testing the Gly of α7nAChR LBD in α7-GlyR chimeric channels 175 and Pro 216 Mutation of Gly 175 Mutation to Lys(α7 G175K -GlyR) showed an increase in the potency of ACh (5-fold) (Table 5). G175K -GlyR, it was also found that nicotine potency was enhanced 10-fold relative to the unmodified α7-GlyR chimeric channel (Table 5). 216 Mutation to Ile(α7 P216I -GlyR) did not substantially change ACh potency (Table 5). However, relative to unmodified α7-GlyR, α7 P216I -GlyR showed increased nicotine potency >4-fold (Table 5). α7 G175K -GlyR and α7 P216I These potency-enhancing mutations in -GlyR also affect the potency of several other α7-GlyR agonists by up to 30-fold (Table 5). G175K -GlyR, a greater than 10-fold potency enhancement relative to α7-GlyR was observed for the clinically used drugs tropisetron, varenicline, cytisine, granisetron, and epibatidine. P216I -GlyR, the potency was enhanced by about 3-fold (Table 5).

[0489]

[0490] For use in ACh-producing organisms, it is important to reduce the endogenous ACh potency at these channels constituted by the α7 nAChR LBD. The mutation G175K can be further combined with other mutations that reduce sensitivity to ACh, such as Y115F and Y210F. Y115F,G175K -GlyR, high potency of agonists based on tropane or quinuclidine core structures was found for tropisetron, granisetron, nortropisetron, PNU-282987, and PHA-543613, and greatly reduced potency for varenicline and cytisine (Table 5). G175K,Y210F -GlyR, the potency of most agonists was considerably reduced, but an enhanced potency was observed for granisetron (Table 5).

[0491] To develop channels with reduced ACh responsiveness but high potency to other agonists, α7 G175K -GlyR in combination with other mutations that increase the potency of specific agonists. Combination with W77F reduces ACh potency, and α7W77F,G175K -GlyR showed increased potency for granisetron, nortropisetron, and tropisetron relative to α7-GlyR, but not for PNU282-987, varenicline, cytisine, or PHA-543613 (Table 5). The combination of G175K and Q79G reduced ACh potency, and α7 Q79G,G175K -GlyR showed increased potency for nortropisetron, PHA-543613, and tropisetron (Table 5). However, no such potency enhancement was observed for other agonists, such as PNU282-987 or varenicline. α7 G175K ,Q139L -GlyR decreased the potency of ACh and increased the potency of nortropisetron and tropisetron (Table 5).

[0492] Further reductions in ACh potency were achieved while maintaining the high potency of synthetic agonists, including those based on tropane and quinuclidine core structures, by incorporating mutations at W77F, Q79G, L141F, Y115F, G175K, and Y210F in various combinations. Q79G,Y115F,G175K -GlyR reduced ACh responsiveness while maintaining a robust response to tropisetron (Table 5). Y115F,G175K These mutations also enhanced responsiveness to other tropane and quinuclidine core structures, particularly quinuclidine thioureas 702 and 703 and tropane esters 723, 725, 726, 736, 737, 738, and 745, relative to α7-5HT3 (representing endogenous α7 nAChR activity) (Table 6). Q79G,Y115F,G175K -GlyR also showed high sensitivity to dihydroavidin (Table 5). α7 W77F,Q79G,G175K -GlyR decreased ACh responsiveness while maintaining high potency responses to tropisetron and nortropisetron (Table 5). α7 W77F,Q79G,G175K -GlyR also showed enhanced potency against additional tropane-based core structures (e.g., compounds 723 and 725) as well as the clinically used drugs mequitazine and promazine (Table 6). W77F,G175K,Y210F -GlyR reduced ACh responsiveness but significantly improved the potency of granisetron (Table 5). α7 L141F,Y115F,G175K -GlyR reduces ACh responsiveness and confers sensitivity to granisetron (Table 5). α7 Q79G,Q139L,G175K -GlyR had reduced ACh responsiveness but showed a potent response to nortropisetron (Table 5).

[0493]

[0494]

[0495]

[0496] α7 G175K -GlyR and α7 P216I -GlyR and mutations at Q79G, Y115F, and G175K are also compatible with the non-binding mutations R27D, E41R, and the GlyR IPD mutation A298G, which further enhance the ligand potency of granisetron, epibatidine, varenicline, cytisine, PNU-282987, tropisetron, nortropisetron, and PHA-543613 (Table 7). R27D,E41R,Q79G,Y115F,G175K The potency of 702, 723, 725 and 726 was further improved, with low ACh responsiveness (Table 6).

[0497] Table 7. Provides the G175K and A298G mutations at the α7GlyR chimeric channel and α7GABAc (also known as GABA A-ρ ) Agonist potency enhancement of W298A at the channel. Unit: μM.

[0498]

[0499] nd = not determined; brackets: SEM

[0500] In #7 Y115F Gly-GlyR chimeric channels 175 Additional amino acid substitutions at α7 also enhanced agonist potency. Y115F The potency of tropisetron at the -GlyR chimeric channel was also enhanced with additional mutations including G175A (7.1-fold), G175F (2-fold), G175H (2.3-fold), G175K (5.6-fold), G175M (2.6-fold), G175R (5.8-fold), G175S (9.3-fold), G175V (16.7-fold).

[0501] Table 8. Agonist potency enhancement by G175 mutation at the α7GlyRY115F chimeric channel. Unit: μM.

[0502]

[0503] nd = not determined; brackets: SEM

[0504] DISCOVERLeu 131 Mutations to smaller amino acids reduce the potency of the canonical agonists ACh and nicotine, while significantly increasing the potency of varenicline, tropisetron, and several other agonists. α7 L131A -GlyR and α7 L131G-GlyR has reduced ACh responsiveness (6-fold) and enhanced potency for varenicline (8-fold and 17-fold, respectively) and tropisetron (2.5-fold and 3.6-fold, respectively) (Table 9). α7 L131G -5HT3 HCs have reduced ACh responsiveness (5-fold) and enhanced potency to varenicline (16-fold) and tropisetron (2.3-fold) ( Fig. 9A and Table 9). α7 L131G,Q139L -GlyR and α7 L131G,Y217F -GlyR showed similar potency enhancement for varenicline relative to α7-GlyR (21-fold), but also decreased ACh sensitivity (-11-fold and -13-fold, respectively). Q79S,L131G -GlyR further improved the potency for varenicline (89-fold) and tropisetron (15-fold). L131G,Q139L,Y217F -GlyR showed the greatest improvement in potency for varenicline (387-fold) and also showed decreased potency for ACh (13-fold) ( Fig. 9B and Table 9). α7 L131G,Q139L,Y217F -GlyR also showed extremely high potency for compound 770 (0.001 μM), compound 773 (0.00034 μM) and compound 774 (0.00013 μM). Figures 11A-11C ). Relative to α7-GlyR, α7 Q79S,L131G,Q139L -GlyR also improved the potency for varenicline (31-fold) and tropisetron (3-fold), but decreased the potency for ACh (9-fold) ( Fig. 9B and Table 9). α7 L131M -GlyR, α7 L131Q -GlyR and α7 L131V -GlyR reduced the potency of ACh, but enhanced the potency of tropisetron, nortropisetron, PHA-543613, and granisetron (Table 9). L131F -GlyR substantially reduced the efficacy of ACh but did not improve the efficacy of other agonists (Table 8). α7 L131G -GABA C Substantially reduced ACh potency but did not improve the potency of other agonists (Table 9). α7 L131G,Q139L,Y217F -5HT3 HC (Table 9) improved the potency of varenicline by 131-fold relative to a7-5HT3 (Table 1). L131G,Q139L,Y217F -5HT3 HC also showed high potency against compound 770 (0.007 μM), compound 773 (0.002 μM) and compound 774 (0.004 μM) (Table 8).

[0505]

[0506]

[0507] Example 7: Chimeric LGICs in Neurons

[0508] The code α7 Q79G -GlyR A298G AAV or DNA plasmids containing nucleic acid of α7Q79G, Y115F, G175K-GlyR chimeric LGIC were transduced into mouse cortical neurons. Low concentrations of tropisetron (30 nM or 100 nM) were applied to mouse cortical neurons. Neuronal activity was silenced by applying low concentrations of agonists ( Figure 7 and Figure 8C ).

[0509] A DNA plasmid containing nucleic acid encoding the α7L131G, Q139L, Y217F-GlyR chimeric LGIC was transfected into mouse cortical neurons. A low concentration of varenicline (10 nM) was applied to mouse cortical neurons. Neuronal activity was silenced by applying a low concentration of an agonist ( Fig. 9C ).

[0510] These results show that modified LGIC activity can be controlled in neurons using low concentrations of the LGIC ligands tropisetron and varenicline.

[0511] Example 8: Varenicline and Varenicline Derivatives and Chimeric LGICs in Therapy

[0512] The smoking cessation medication varenicline is a potent partial a4b2 agonist. Varenicline is also a moderate a7 nAChR agonist and a 5HT3 agonist. It has excellent brain penetration.

[0513] Compared with the unmodified chimeric channels α7-GlyR and α7-5HT3, the chimeric channel α7 L131G,Q139L,Y217F -GlyR and α7 L131G,Q139L,Y217F -5HT3 HCs have enhanced binding potency for the ligand varenicline. However, varenicline activates endogenous ion channels such as α7nACHR, α4β2nAChR, and serotonin receptor 3 (5HT3-R), so it is desirable to obtain varenicline derivatives with high potency at engineered channels but reduced potency at these endogenous targets.

[0514] Using the crystal structure of varenicline bound to acetylcholine binding protein, it was found that the molecule contacts residue V106, which is homologous to L131 in the a7 nAChR sequence. A mutation to L131G improved varenicline potency 20-fold while reducing ACh potency 5-fold ( Fig. 9A ).

[0515] Additional mutations to L131G were made to further reduce Ach potency and improve varenicline potency. In most cases, the changes in potency were relevant for both molecules, but a subset of mutations selectively enhanced varenicline potency by 360-fold and reduced Ach potency by 20-fold ( Fig. 9B and 9C The response to 10nM varenicline can be seen on the right, compared to 300uM Ach ( Fig.9D ). These chimeric channels show a characteristic slow activation, which acts as a low-pass filter for transient fluctuations in ACh. It should also be noted that despite the high potency of the channel, it does not have any ligand-independent activity, as shown by brief application of the channel antagonist picrotoxin before the addition of these ligands. Ligand-independent activity will be recorded as outward currents in this trace. When the chimeric channels are expressed in cortical neurons, 10 nM varenicline induces super-strong neuronal silencing ( Fig.9E ).

[0516] In vivo activity was also very potent in unilateral substantia nigra (SNr) silencing experiments. Circulation contralateral to the silenced SNr was seen at doses above 0.1 mg / kg (mpk). Varenicline potency was seen to be 10-fold improved over antinicotinic activity ( Fig.10 ).

[0517] Varenicline derivatives are engineered to reduce or eliminate endogenous varenicline activity. The potency of varenicline and each varenicline derivative was determined on a variety of chimeric channels (Table 10).

[0518] Table 10. Potency (EC50, μM) of varenicline and varenicline derivatives at chimeric channels and compared with agonist potency at 5HT3-R and α4β2 nAChR.

[0519]

[0520]

[0521] nd = not determined; brackets: SEM

[0522] Table 10 shows specific chemical structures of LGIC agonists with similarities to α7 L131G,Q139L,Y217F -GlyR or α7 L131G ,Q139L,Y217F -5HT3 HC has a high potency compatible substitution pattern.

[0523] All molecules in Table 10 showed reduced sensitivity to α7-GlyR and α7-5HT3 (which act as surrogates for α7 nAChR efficacy). Compound 780, Compound 783, Compound 789, Compound 790, Compound 791, Compound 792, Compound 793, Compound 795, Compound 798, Compound 802, Compound 803, Compound 804, Compound 805, Compound 807, Compound 808, Compound 812 and Compound 813 showed reduced sensitivity to α7 L131G,Q139L,Y217F -GlyR or α7 L131G,Q139L,Y217F Compound 780, Compound 783, Compound 791, Compound 792, Compound 793, Compound 798, Compound 802, Compound 803, Compound 807 or Compound 808 showed an effect on α7 L131G,Q139L,Y217F -GlyR or α7 L131G,Q139L,Y217F -5HT3 HC has an efficacy of less than 10 nM. Compounds 792, 795, 802 and 808 showed an efficacy against α7 L131G,Q139L,Y217F -GlyR or α7 L131G,Q139L,Y217F -5HT3 HC has a potency of less than 10 nM and a potency of >1 μM at 5HT3-R, and a potency of >10 μM at α4β2 nAChR.

[0524] Evaluation of chemical genetic perturbations of cortical neuron activity. Due to reduced input resistance and elevated base strength, in neurons expressing PSAM 4 Varenicline strongly inhibits action potential firing in neurons expressing -GlyR. Cortical layer 2 / 3 neuron membrane properties in PSAM 4 Varenicline expression in PSAM-expressing neurons was similar to that in mixed untransfected control neurons. 4 -5HT3HC depolarizes neurons and initiates firing. Membrane properties of cortical layer 2 / 3 neurons in PSAM 4 -5HT3 HC expressing neurons and mixed untransfected control neurons were similar. See e.g. Figures 12A-12F .

[0525] PSAM was evaluated in mice 4 Silencing of GlyR neurons. 4 -GlyR-IRES-EGFP is unilaterally targeted to the SNr. Low doses of intraperitoneal varenicline trigger expression of PSAM 4-GlyR-expressing mice, but not sham-operated or mice expressing EGFP alone. Two doses of varenicline 5 hours apart gave similar proportions of total rotations, indicating tachyphylaxis without chemogenetic responses. The duration of chemogenetic silencing monitored by the time course of rotational responses was normalized to the maximum rotation of each mouse. See e.g. Figures 13A-13D .

[0526] Superpotent chemical genetic agonists were evaluated. 4 uPSEM agonist EC50s were compared at the channel and endogenous varenicline target, and compared to the IC50 against α4β2 nAChR at 1 μM Chl. 792 α4β2nAChR and uPSEM 817 10% partial agonist of α4β2nAChR. 792 、uPSEM 793 、uPSEM 815 and uPSEM 817 Strongly inhibits PSAM expression by reducing the current required to fire action potentials (basal strength) 4 -GlyR firing in cortical neurons. See e.g. Figures 14A-14J .

[0527] We evaluated unilateral expression of PSAM in the SNr. 4 -GlyR-induced uPSEM dose response in vivo in mice. See e.g. Figures 15A-15H .

[0528] Varenicline derivatives are engineered to reduce or eliminate endogenous varenicline activity. The potency of varenicline and each varenicline derivative was determined for a variety of chimeric channels (Table 11).

[0529] Table 11. EC50 of varenicline and derivatives at chimeric channels MP (μM) and comparison of agonist potency at 5HT3-R and α4β2 nAChR. In vivo potency was determined in the SNr silencing rotation assay in mice. nd: not determined. nr: no response. Values ​​are mean ± SEM.

[0530]

[0531] Ethoxylated and propoxylated compounds (uPSEM) 815 and 817 in PSAM 4 -GlyR produces subnanomolar potency. uPSEM 817 Agonist selectivity is excellent, with 5000-fold to 10,000-fold selectivity against PSAM relative to α7-GlyR, α7-5HT3, and 5HT3-R4 -GlyR selectivity. uPSEM 815 and uPSEM 817 Up to 30 μM, no significant α4β2 nAChR agonism was observed, and uPSEM 815 had >2000-fold greater agonism against PSAM relative to 5HT3-R. 4 -GlyR selectivity.

[0532] Example 9: Chimeric LGICs in Therapy

[0533] Chemical genetics (chemogenetic) tools provide an attractive strategy for drug and gene combination therapy. This is because it is possible to use exogenously delivered ion channels selectively engaged by administering drugs, using the same ion channels and ligands, to regulate cell function in a consistent manner across different cell types in a variety of indications. The identification of ion channels gated by well-tolerated clinically used drugs is particularly attractive for potentially extending chemical genetics to human therapeutic uses.

[0534] For the drug tropisetron, we found that it activated α7 with an EC50 of 11 nM. Q79G -GlyR A298G , which is similar to the reported IC50 of 10 nM tropisetron for its therapeutic target 5HT3 receptor (Combrink et al 2009 Pharmacological reports: PR 61:785-97).

[0535] Other Implementations

[0536] It should be understood that although the disclosure has been described in conjunction with its detailed description, the foregoing description is intended to illustrate and not limit the scope of the disclosure, which is defined by the scope of the appended claims. Other aspects, advantages and modifications are within the scope of the appended claims.

Claims

1. Use of a modified ligand-gated ion channel (LGIC) or a nucleic acid encoding the modified LGIC in the preparation of a pharmaceutical composition for treating a channelopathy in a mammal, wherein the pharmaceutical composition is used in a method comprising: administering the modified LGIC or a nucleic acid encoding the modified LGIC to a cell in the mammal; and administering an exogenous LGIC ligand to the mammal, The modified LGIC comprises at least one modified LGIC subunit, wherein the modified LGIC subunit comprises: A human α7 nicotinic acetylcholine receptor (α7-nAChR) ligand binding domain (LBD) comprising an L131G amino acid substitution, a Q139L amino acid substitution, and a Y217F amino acid substitution, and An ion pore domain (IPD), wherein the IPD is an IPD from a receptor selected from the group consisting of a glycine receptor (GlyR) IPD, a serotonin 3 receptor (5HT3) IPD, a gamma-aminobutyric acid (GABA) receptor IPD, and an α7 nicotinic acetylcholine receptor (α7-nAChR) IPD, and wherein the exogenous LGIC ligand selectively binds to the modified LGIC, and wherein the exogenous LGIC ligand that selectively binds to the modified LGIC is selected from the following group: Compound 0780, Compound 0782, Compound 0785, Compound 0788, Compound 0789, Compound 0791, Compound 0793, Compound 0794, Compound 0795, Compound 0798, Compound 0799, Compound 0800, Compound 0801, Compound 0802, Compound 0803, Compound 0804, Compound 0805, Compound 0807, Compound 0808, Compound 0812, Compound 0813, Compound 0783, Compound 0784, Compound 0790 and Compound 0792.

2. The method of claim 1, wherein the channelopathy is selected from the group consisting of Bartter syndrome, Brugada syndrome, catecholamine-dependent ventricular tachycardia (CPVT), congenital hyperinsulinemia, cystic fibrosis, Dravet syndrome, paroxysmal ataxia, erythromelalgia, generalized epilepsy (e.g., with febrile seizures), familial hemiplegic migraine, fibromyalgia, hyperkalemic periodic paralysis, hypokalemic periodic paralysis, Lambert myasthenic syndrome, long QT syndrome (e.g., Romano-Ward syndrome), short QT syndrome, malignant hyperthermia, mucolipidosis type IV, myasthenia gravis, myotonia congenita, neuromyelitis optica, neuromyotonia, nonsyndromic deafness, paramyotonia congenita, retinitis pigmentosa, timothy syndrome, tinnitus, seizures, trigeminal neuralgia, and multiple sclerosis.

3. Use of a modified ligand-gated ion channel (LGIC) or a nucleic acid encoding the modified LGIC in the preparation of a pharmaceutical composition for regulating ion transport across the cell membrane of a mammalian cell, wherein the pharmaceutical composition is used in a method comprising: administering the modified LGIC or a nucleic acid encoding the modified LGIC to the cell; and administering an exogenous LGIC ligand to the mammal, The modified LGIC comprises at least one modified LGIC subunit, wherein the modified LGIC subunit comprises: A human α7 nicotinic acetylcholine receptor (α7-nAChR) ligand binding domain (LBD) comprising an L131G amino acid substitution, a Q139L amino acid substitution, and a Y217F amino acid substitution, and An ion pore domain (IPD), wherein the IPD is an IPD from a receptor selected from the group consisting of a glycine receptor (GlyR) IPD, a serotonin 3 receptor (5HT3) IPD, a gamma-aminobutyric acid (GABA) receptor IPD, and an α7 nicotinic acetylcholine receptor (α7-nAChR) IPD, and wherein the exogenous LGIC ligand selectively binds to the modified LGIC, and wherein the exogenous LGIC ligand that selectively binds to the modified LGIC is selected from the following group: Compound 0780, Compound 0782, Compound 0785, Compound 0788, Compound 0789, Compound 0791, Compound 0793, Compound 0794, Compound 0795, Compound 0798, Compound 0799, Compound 0800, Compound 0801, Compound 0802, Compound 0803, Compound 0804, Compound 0805, Compound 0807, Compound 0808, Compound 0812, Compound 0813, Compound 0783, Compound 0784, Compound 0790 and Compound 0792.

4. The use of claim 3, wherein the modulation comprises activating ion transport.

5. The use of claim 3, wherein the modulation comprises inhibiting ion transport.

6. The use of claim 3, wherein the cells are selected from the group consisting of neurons, glial cells, muscle cells, stem cells, endocrine cells and immune cells.

7. The use of claim 3, wherein administering the modified LGIC to the cell comprises administering in vivo.

8. The use of claim 3, wherein administering the modified LGIC to the cell comprises ex vivo administration.

9. Use of a modified ligand-gated ion channel (LGIC) or a nucleic acid encoding the modified LGIC in the preparation of a pharmaceutical composition for regulating cell excitability in a mammal, wherein the pharmaceutical composition is used in a method comprising: administering the modified LGIC or a nucleic acid encoding the modified LGIC to the cell; and administering an exogenous LGIC ligand to the mammal, The modified LGIC comprises at least one modified LGIC subunit, wherein the modified LGIC subunit comprises: A human α7 nicotinic acetylcholine receptor (α7-nAChR) ligand binding domain (LBD) comprising an L131G amino acid substitution, a Q139L amino acid substitution, and a Y217F amino acid substitution, and An ion pore domain (IPD), wherein the IPD is an IPD from a receptor selected from the group consisting of a glycine receptor (GlyR) IPD, a serotonin 3 receptor (5HT3) IPD, a gamma-aminobutyric acid (GABA) receptor IPD, and an α7 nicotinic acetylcholine receptor (α7-nAChR) IPD, and wherein the exogenous LGIC ligand selectively binds to the modified LGIC, and wherein the exogenous LGIC ligand that selectively binds to the modified LGIC is selected from the following group: Compound 0780, Compound 0782, Compound 0785, Compound 0788, Compound 0789, Compound 0791, Compound 0793, Compound 0794, Compound 0795, Compound 0798, Compound 0799, Compound 0800, Compound 0801, Compound 0802, Compound 0803, Compound 0804, Compound 0805, Compound 0807, Compound 0808, Compound 0812, Compound 0813, Compound 0783, Compound 0784, Compound 0790 and Compound 0792.

10. The use of claim 9, wherein the modulation comprises increasing the excitability of the cells.

11. The method of claim 9, wherein said regulation comprises reducing the excitability of said cells.

12. The use of claim 9, wherein the cell is an excitable cell.

13. The use of claim 9, wherein the cells are selected from the group consisting of neurons, glial cells, muscle cells, stem cells, endocrine cells and immune cells.

14. The use of claim 9, wherein administering the modified LGIC to the cell comprises administering in vivo.

15. The use of claim 9, wherein administering the modified LGIC to the cell comprises ex vivo administration.

16. Use of a modified ligand-gated ion channel (LGIC) or a nucleic acid encoding the modified LGIC in the preparation of a pharmaceutical composition for regulating cell activity in a mammal, wherein the pharmaceutical composition is used in a method comprising: administering the modified LGIC or a nucleic acid encoding the modified LGIC to the cell; and administering an exogenous LGIC ligand to the mammal, The modified LGIC comprises at least one modified LGIC subunit, wherein the modified LGIC subunit comprises: A human α7 nicotinic acetylcholine receptor (α7-nAChR) ligand binding domain (LBD) comprising an L131G amino acid substitution, a Q139L amino acid substitution, and a Y217F amino acid substitution, and An ion pore domain (IPD), wherein the IPD is an IPD from a receptor selected from the group consisting of a glycine receptor (GlyR) IPD, a serotonin 3 receptor (5HT3) IPD, a gamma-aminobutyric acid (GABA) receptor IPD, and an α7 nicotinic acetylcholine receptor (α7-nAChR) IPD, and wherein the exogenous LGIC ligand selectively binds to the modified LGIC, and wherein the exogenous LGIC ligand that selectively binds to the modified LGIC is selected from the following group: Compound 0780, Compound 0782, Compound 0785, Compound 0788, Compound 0789, Compound 0791, Compound 0793, Compound 0794, Compound 0795, Compound 0798, Compound 0799, Compound 0800, Compound 0801, Compound 0802, Compound 0803, Compound 0804, Compound 0805, Compound 0807, Compound 0808, Compound 0812, Compound 0813, Compound 0783, Compound 0784, Compound 0790 and Compound 0792.

17. The use of claim 16, wherein said modulation comprises increasing the activity of said cells.

18. The use of claim 16, wherein said modulation comprises reducing the activity of said cell.

19. The use of claim 16, wherein the activity is selected from the group consisting of ion transport, passive transport, excitation, inhibition, and exocytosis.

20. The use of claim 16, wherein the cells are selected from the group consisting of neurons, glial cells, muscle cells, stem cells, endocrine cells, and immune cells.

21. The use of claim 16, wherein administering the modified LGIC to cells from the mammal comprises administering in vivo.

22. The use of claim 16, wherein administering the modified LGIC to a cell from the mammal comprises ex vivo administration.

23. The use of any one of claims 1-22, wherein administering the modified LGIC to the cell comprises administering a nucleic acid encoding the modified LGIC.

24. The use of any one of claims 1-22, wherein the modified LGIC comprises a sequence that is at least 85% identical to SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 or SEQ ID NO:

10.

25. The use of claim 24, wherein the modified LGIC comprises a sequence that is at least 90% identical to SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 or SEQ ID NO:

10.

26. The use of claim 25, wherein the modified LGIC comprises a sequence that is at least 95% identical to SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:

10.

27. The use of claim 26, wherein the modified LGIC comprises the sequence shown in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:

10.

28. The use of any one of claims 1-22, wherein the IPD comprises at least one modified amino acid.

29. The use of any one of claims 1-22, wherein the IPD is a GlyR IPD.

30. The use of claim 28, wherein the IPD is a GlyR IPD, and wherein the at least one modified amino acid comprises an amino acid substitution at residue 298 of the modified LGIC.

31. The use of claim 30, wherein the amino acid substitution at residue 298 of the modified LGIC is an A298G substitution.

32. The use of claim 28, wherein the IPD is a GABA IPD, and wherein the at least one modified amino acid in the GABA IPD comprises an amino acid substitution at residue 298 of the modified LGIC.

33. The use of claim 32, wherein the amino acid substitution at residue 298 of the chimeric LGIC is a W298A substitution.

34. Use of a homomeric chimeric ligand-gated ion channel (LGIC) or a nucleic acid encoding said LGIC in the preparation of a pharmaceutical composition for treating a channelopathy in a mammal, wherein said pharmaceutical composition is used in a method comprising: administering the LGIC or a nucleic acid encoding the LGIC to a cell in the mammal; and administering said ligand to said mammal, The LGIC comprises chimeric LGIC subunits, each chimeric LGIC subunit comprising: an α7 nicotinic acetylcholine receptor ligand binding domain having an L131G amino acid substitution, a Q139L amino acid substitution, and a Y217F amino acid substitution; and an ion pore domain selected from the group consisting of a glycine receptor ion pore domain and a serotonin 3 receptor ion pore domain; wherein the exogenous LGIC ligand selectively binds to the chimeric LGIC, wherein the exogenous LGIC ligand that selectively binds to the chimeric LGIC is selected from the group consisting of Compound 0780, Compound 0782, Compound 0785, Compound 0788, Compound 0789, Compound 0791, Compound 0793, Compound 0794, Compound 0795, Compound 0798, Compound 0799, Compound 0800, Compound 0801, Compound 0802, Compound 0803, Compound 0804, Compound 0805, Compound 0807, Compound 0808, Compound 0812, Compound 0813, Compound 0783, Compound 0784, Compound 0790, and Compound 0792, And wherein the chimeric LGIC minimally binds acetylcholine (ACh).

35. Use of a homomeric chimeric ligand-gated ion channel (LGIC) or a nucleic acid encoding said LGIC in the preparation of a pharmaceutical composition for regulating cell excitability in a mammal, wherein said pharmaceutical composition is used in a method comprising: administering the LGIC or a nucleic acid encoding the LGIC to a cell in the mammal; and administering said ligand to said mammal, The LGIC comprises chimeric LGIC subunits, each chimeric LGIC subunit comprising: an α7 nicotinic acetylcholine receptor ligand binding domain having an L131G amino acid substitution, a Q139L amino acid substitution, and a Y217F amino acid substitution; and an ion pore domain selected from the group consisting of a glycine receptor ion pore domain and a serotonin 3 receptor ion pore domain; wherein the exogenous LGIC ligand selectively binds to the chimeric LGIC, wherein the exogenous LGIC ligand that selectively binds to the chimeric LGIC is selected from the group consisting of Compound 0780, Compound 0782, Compound 0785, Compound 0788, Compound 0789, Compound 0791, Compound 0793, Compound 0794, Compound 0795, Compound 0798, Compound 0799, Compound 0800, Compound 0801, Compound 0802, Compound 0803, Compound 0804, Compound 0805, Compound 0807, Compound 0808, Compound 0812, Compound 0813, Compound 0783, Compound 0784, Compound 0790, and Compound 0792, And wherein the chimeric LGIC minimally binds acetylcholine (ACh).

36. Use of a homomeric chimeric ligand-gated ion channel (LGIC) or a nucleic acid encoding said LGIC in the preparation of a pharmaceutical composition for regulating cell activity in a mammal, wherein said pharmaceutical composition is used in a method comprising: administering the LGIC or a nucleic acid encoding the LGIC to a cell in the mammal; and administering said ligand to said mammal, The LGIC comprises chimeric LGIC subunits, each chimeric LGIC subunit comprising: an α7 nicotinic acetylcholine receptor ligand binding domain having an L131G amino acid substitution, a Q139L amino acid substitution, and a Y217F amino acid substitution; and an ion pore domain selected from the group consisting of a glycine receptor ion pore domain and a serotonin 3 receptor ion pore domain; wherein the exogenous LGIC ligand selectively binds to the chimeric LGIC, wherein the exogenous LGIC ligand that selectively binds to the chimeric LGIC is selected from the group consisting of Compound 0780, Compound 0782, Compound 0785, Compound 0788, Compound 0789, Compound 0791, Compound 0793, Compound 0794, Compound 0795, Compound 0798, Compound 0799, Compound 0800, Compound 0801, Compound 0802, Compound 0803, Compound 0804, Compound 0805, Compound 0807, Compound 0808, Compound 0812, Compound 0813, Compound 0783, Compound 0784, Compound 0790, and Compound 0792, And wherein the chimeric LGIC minimally binds acetylcholine (ACh).